<?xml version="1.0" encoding="UTF-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1994-10-01" modified="2019-07-31" version="249">
<accession>P38398</accession>
<accession>E9PFZ0</accession>
<accession>O15129</accession>
<accession>Q1RMC1</accession>
<accession>Q3LRJ0</accession>
<accession>Q3LRJ6</accession>
<accession>Q6IN79</accession>
<accession>Q7KYU9</accession>
<name>BRCA1_HUMAN</name>
<protein>
<recommendedName>
<fullName>Breast cancer type 1 susceptibility protein</fullName>
<ecNumber evidence="23 41 42 58 64 74">2.3.2.27</ecNumber>
</recommendedName>
<alternativeName>
<fullName>RING finger protein 53</fullName>
</alternativeName>
<alternativeName>
<fullName evidence="110">RING-type E3 ubiquitin transferase BRCA1</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">BRCA1</name>
<name type="synonym">RNF53</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1994" name="Science" volume="266" first="66" last="71">
<title>A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.</title>
<authorList>
<person name="Miki Y."/>
<person name="Swensen J."/>
<person name="Shattuck-Eidens D."/>
<person name="Futreal P.A."/>
<person name="Harshman K."/>
<person name="Tavtigian S."/>
<person name="Liu Q."/>
<person name="Cochran C."/>
<person name="Bennett L.M."/>
<person name="Ding W."/>
<person name="Bell R."/>
<person name="Rosenthal J."/>
<person name="Hussey C."/>
<person name="Tran T."/>
<person name="McClure M."/>
<person name="Frye C."/>
<person name="Hattier T."/>
<person name="Phelps R."/>
<person name="Haugen-Strano A."/>
<person name="Katcher H."/>
<person name="Yakumo K."/>
<person name="Gholami Z."/>
<person name="Shaffer D."/>
<person name="Stone S."/>
<person name="Bayer S."/>
<person name="Wray C."/>
<person name="Bogden R."/>
<person name="Dayananth P."/>
<person name="Ward J."/>
<person name="Tonin P."/>
<person name="Narod S."/>
<person name="Bristow P.K."/>
<person name="Norris F.H."/>
<person name="Helvering L."/>
<person name="Morrison P."/>
<person name="Rosteck P."/>
<person name="Lai M."/>
<person name="Barrett J.C."/>
<person name="Lewis C."/>
<person name="Neuhausen S."/>
<person name="Cannon-Albright L."/>
<person name="Godlgar D."/>
<person name="Wiseman R."/>
<person name="Kamb A."/>
<person name="Skolnick M.H."/>
</authorList>
<dbReference type="PubMed" id="7545954"/>
<dbReference type="DOI" id="10.1126/science.7545954"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>VARIANT BC ARG-1775</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1996" name="Genome Res." volume="6" first="1029" last="1049">
<title>Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.</title>
<authorList>
<person name="Smith T.M."/>
<person name="Lee M.K."/>
<person name="Szabo C.I."/>
<person name="Jerome N."/>
<person name="McEuen M."/>
<person name="Taylor M."/>
<person name="Hood L."/>
<person name="King M.-C."/>
</authorList>
<dbReference type="PubMed" id="8938427"/>
<dbReference type="DOI" id="10.1101/gr.6.11.1029"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="journal article" date="1997" name="Oncogene" volume="14" first="1" last="16">
<title>Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.</title>
<authorList>
<person name="Wilson C.A."/>
<person name="Payton M.N."/>
<person name="Elliott G.S."/>
<person name="Buaas F.W."/>
<person name="Cajulis E.E."/>
<person name="Grosshans D."/>
<person name="Ramos L."/>
<person name="Reese D.M."/>
<person name="Slamon D.J."/>
<person name="Calzone F.J."/>
</authorList>
<dbReference type="PubMed" id="9010228"/>
<dbReference type="DOI" id="10.1038/sj.onc.1200924"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>SUBCELLULAR LOCATION (ISOFORM 2)</scope>
<scope>VARIANTS ARG-239 AND GLY-1613</scope>
<scope>TISSUE SPECIFICITY (ISOFORMS 1 AND 3)</scope>
<source>
<tissue>Mammary gland</tissue>
</source>
</reference>
<reference key="4">
<citation type="submission" date="1997-05" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Holt J.T."/>
<person name="Robinson-Benion C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<source>
<tissue>Testis</tissue>
</source>
</reference>
<reference key="5">
<citation type="submission" date="2005-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Raymond C.K."/>
<person name="Paddock M."/>
<person name="Subramanian S."/>
<person name="Deodato C."/>
<person name="Zhou Y."/>
<person name="Haugen E."/>
<person name="Kaul R."/>
<person name="Olson M.V."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANT ARG-356</scope>
</reference>
<reference key="6">
<citation type="submission" date="2003-04" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS SER-275; ARG-356; ASN-693; LEU-871; GLY-1038; ASN-1040; GLY-1140; ARG-1183; GLY-1613 AND ALA-1620</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2006" name="Nature" volume="440" first="1045" last="1049">
<title>DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.</title>
<authorList>
<person name="Zody M.C."/>
<person name="Garber M."/>
<person name="Adams D.J."/>
<person name="Sharpe T."/>
<person name="Harrow J."/>
<person name="Lupski J.R."/>
<person name="Nicholson C."/>
<person name="Searle S.M."/>
<person name="Wilming L."/>
<person name="Young S.K."/>
<person name="Abouelleil A."/>
<person name="Allen N.R."/>
<person name="Bi W."/>
<person name="Bloom T."/>
<person name="Borowsky M.L."/>
<person name="Bugalter B.E."/>
<person name="Butler J."/>
<person name="Chang J.L."/>
<person name="Chen C.-K."/>
<person name="Cook A."/>
<person name="Corum B."/>
<person name="Cuomo C.A."/>
<person name="de Jong P.J."/>
<person name="DeCaprio D."/>
<person name="Dewar K."/>
<person name="FitzGerald M."/>
<person name="Gilbert J."/>
<person name="Gibson R."/>
<person name="Gnerre S."/>
<person name="Goldstein S."/>
<person name="Grafham D.V."/>
<person name="Grocock R."/>
<person name="Hafez N."/>
<person name="Hagopian D.S."/>
<person name="Hart E."/>
<person name="Norman C.H."/>
<person name="Humphray S."/>
<person name="Jaffe D.B."/>
<person name="Jones M."/>
<person name="Kamal M."/>
<person name="Khodiyar V.K."/>
<person name="LaButti K."/>
<person name="Laird G."/>
<person name="Lehoczky J."/>
<person name="Liu X."/>
<person name="Lokyitsang T."/>
<person name="Loveland J."/>
<person name="Lui A."/>
<person name="Macdonald P."/>
<person name="Major J.E."/>
<person name="Matthews L."/>
<person name="Mauceli E."/>
<person name="McCarroll S.A."/>
<person name="Mihalev A.H."/>
<person name="Mudge J."/>
<person name="Nguyen C."/>
<person name="Nicol R."/>
<person name="O'Leary S.B."/>
<person name="Osoegawa K."/>
<person name="Schwartz D.C."/>
<person name="Shaw-Smith C."/>
<person name="Stankiewicz P."/>
<person name="Steward C."/>
<person name="Swarbreck D."/>
<person name="Venkataraman V."/>
<person name="Whittaker C.A."/>
<person name="Yang X."/>
<person name="Zimmer A.R."/>
<person name="Bradley A."/>
<person name="Hubbard T."/>
<person name="Birren B.W."/>
<person name="Rogers J."/>
<person name="Lander E.S."/>
<person name="Nusbaum C."/>
</authorList>
<dbReference type="PubMed" id="16625196"/>
<dbReference type="DOI" id="10.1038/nature04689"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 7)</scope>
<scope>VARIANTS LEU-871; GLY-1038; ARG-1183; GLY-1613 AND ILE-1652</scope>
<source>
<tissue>PNS</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="2000" name="Oncogene" volume="19" first="2767" last="2773">
<title>Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa).</title>
<authorList>
<person name="Liu J."/>
<person name="Prolla G."/>
<person name="Rostagno A."/>
<person name="Chiarle R."/>
<person name="Feiner H."/>
<person name="Inghirami G."/>
</authorList>
<dbReference type="PubMed" id="10851077"/>
<dbReference type="DOI" id="10.1038/sj.onc.1203599"/>
</citation>
<scope>PROTEIN SEQUENCE OF 6-18 (ISOFORM 1)</scope>
<scope>PROTEIN SEQUENCE OF 18-26 (ISOFORM 4)</scope>
<scope>ALTERNATIVE INITIATION (ISOFORM 4)</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1997" name="Mol. Cell. Biol." volume="17" first="444" last="452">
<title>Localization of BRCA1 and a splice variant identifies the nuclear localization signal.</title>
<authorList>
<person name="Thakur S."/>
<person name="Zhang H.B."/>
<person name="Peng Y."/>
<person name="Le H."/>
<person name="Carroll B."/>
<person name="Ward T."/>
<person name="Yao J."/>
<person name="Farid L.M."/>
<person name="Couch F.J."/>
<person name="Wilson R.B."/>
<person name="Weber B.L."/>
</authorList>
<dbReference type="PubMed" id="8972225"/>
<dbReference type="DOI" id="10.1128/MCB.17.1.444"/>
</citation>
<scope>ALTERNATIVE SPLICING (ISOFORM 5)</scope>
<scope>SUBCELLULAR LOCATION (ISOFORM 5)</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1998" name="Nat. Genet." volume="19" first="254" last="256">
<title>BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.</title>
<authorList>
<person name="Anderson S.F."/>
<person name="Schlegel B.P."/>
<person name="Nakajima T."/>
<person name="Wolpin E.S."/>
<person name="Parvin J.D."/>
</authorList>
<dbReference type="PubMed" id="9662397"/>
<dbReference type="DOI" id="10.1038/930"/>
</citation>
<scope>INTERACTION WITH DHX9</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1998" name="Oncogene" volume="16" first="1097" last="1112">
<title>BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.</title>
<authorList>
<person name="Jensen D.E."/>
<person name="Proctor M."/>
<person name="Marquis S.T."/>
<person name="Gardner H.P."/>
<person name="Ha S.I."/>
<person name="Chodosh L.A."/>
<person name="Ishov A.M."/>
<person name="Tommerup N."/>
<person name="Vissing H."/>
<person name="Sekido Y."/>
<person name="Minna J."/>
<person name="Borodovsky A."/>
<person name="Schultz D.C."/>
<person name="Wilkinson K.D."/>
<person name="Maul G.G."/>
<person name="Barlev N."/>
<person name="Berger S."/>
<person name="Prendergast G.C."/>
<person name="Rauscher F.J. III"/>
</authorList>
<dbReference type="PubMed" id="9528852"/>
<dbReference type="DOI" id="10.1038/sj.onc.1201861"/>
</citation>
<scope>INTERACTION WITH BAP1</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>VARIANTS GLY-61 AND GLY-64</scope>
<scope>MUTAGENESIS OF ARG-71</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1998" name="Oncogene" volume="17" first="2279" last="2285">
<title>Characterization of a carboxy-terminal BRCA1 interacting protein.</title>
<authorList>
<person name="Wong A.K."/>
<person name="Ormonde P.A."/>
<person name="Pero R."/>
<person name="Chen Y."/>
<person name="Lian L."/>
<person name="Salada G."/>
<person name="Berry S."/>
<person name="Lawrence Q."/>
<person name="Dayananth P."/>
<person name="Ha P."/>
<person name="Tavtigian S.V."/>
<person name="Teng D.H."/>
<person name="Bartel P.L."/>
</authorList>
<dbReference type="PubMed" id="9811458"/>
<dbReference type="DOI" id="10.1038/sj.onc.1202150"/>
</citation>
<scope>INTERACTION WITH RBBP8</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1999" name="Proc. Natl. Acad. Sci. U.S.A." volume="96" first="11364" last="11369">
<title>RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination.</title>
<authorList>
<person name="Lorick K.L."/>
<person name="Jensen J.P."/>
<person name="Fang S."/>
<person name="Ong A.M."/>
<person name="Hatakeyama S."/>
<person name="Weissman A.M."/>
</authorList>
<dbReference type="PubMed" id="10500182"/>
<dbReference type="DOI" id="10.1073/pnas.96.20.11364"/>
</citation>
<scope>FUNCTION AS AN E2-DEPENDENT UBIQUITIN-PROTEIN LIGASE</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2000" name="Genes Dev." volume="14" first="927" last="939">
<title>BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.</title>
<authorList>
<person name="Wang Y."/>
<person name="Cortez D."/>
<person name="Yazdi P."/>
<person name="Neff N."/>
<person name="Elledge S.J."/>
<person name="Qin J."/>
</authorList>
<dbReference type="PubMed" id="10783165"/>
</citation>
<scope>IDENTIFICATION IN THE BASC COMPLEX</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2000" name="Genes Dev." volume="14" first="2989" last="3002">
<title>Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.</title>
<authorList>
<person name="Tibbetts R.S."/>
<person name="Cortez D."/>
<person name="Brumbaugh K.M."/>
<person name="Scully R."/>
<person name="Livingston D."/>
<person name="Elledge S.J."/>
<person name="Abraham R.T."/>
</authorList>
<dbReference type="PubMed" id="11114888"/>
<dbReference type="DOI" id="10.1101/gad.851000"/>
</citation>
<scope>PHOSPHORYLATION AT SER-1143; SER-1280; SER-1387; THR-1394; SER-1423 AND SER-1457</scope>
<scope>MUTAGENESIS OF SER-1143; SER-1239; SER-1280; SER-1298; SER-1330; SER-1387; THR-1394; SER-1423; SER-1457; SER-1466; SER-1524 AND SER-1755</scope>
<scope>CHARACTERIZATION OF VARIANT BC ALA-1720</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2000" name="Nature" volume="404" first="201" last="204">
<title>hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.</title>
<authorList>
<person name="Lee J.S."/>
<person name="Collins K.M."/>
<person name="Brown A.L."/>
<person name="Lee C.H."/>
<person name="Chung J.H."/>
</authorList>
<dbReference type="PubMed" id="10724175"/>
<dbReference type="DOI" id="10.1038/35004614"/>
</citation>
<scope>FUNCTION IN DNA DAMAGE RESPONSE</scope>
<scope>PHOSPHORYLATION AT SER-988 BY CHEK2</scope>
<scope>INTERACTION WITH CHEK2</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2001" name="Cell" volume="105" first="149" last="160">
<title>BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.</title>
<authorList>
<person name="Cantor S.B."/>
<person name="Bell D.W."/>
<person name="Ganesan S."/>
<person name="Kass E.M."/>
<person name="Drapkin R."/>
<person name="Grossman S."/>
<person name="Wahrer D.C.R."/>
<person name="Sgroi D.C."/>
<person name="Lane W.S."/>
<person name="Haber D.A."/>
<person name="Livingston D.M."/>
</authorList>
<dbReference type="PubMed" id="11301010"/>
<dbReference type="DOI" id="10.1016/S0092-8674(01)00304-X"/>
</citation>
<scope>INTERACTION WITH BRIP1</scope>
<scope>CHARACTERIZATION OF VARIANT OVARIAN CANCER ARG-1749</scope>
<scope>CHARACTERIZATION OF VARIANT BC ARG-1775</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2001" name="J. Cell Biol." volume="155" first="911" last="921">
<title>BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations.</title>
<authorList>
<person name="Ye Q."/>
<person name="Hu Y.-F."/>
<person name="Zhong H."/>
<person name="Nye A.C."/>
<person name="Belmont A.S."/>
<person name="Li R."/>
</authorList>
<dbReference type="PubMed" id="11739404"/>
<dbReference type="DOI" id="10.1083/jcb.200108049"/>
</citation>
<scope>INTERACTION WITH NELFB</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2001" name="Mol. Cell" volume="7" first="249" last="262">
<title>Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.</title>
<authorList>
<person name="Garcia-Higuera I."/>
<person name="Taniguchi T."/>
<person name="Ganesan S."/>
<person name="Meyn M.S."/>
<person name="Timmers C."/>
<person name="Hejna J."/>
<person name="Grompe M."/>
<person name="D'Andrea A.D."/>
</authorList>
<dbReference type="PubMed" id="11239454"/>
<dbReference type="DOI" id="10.1016/S1097-2765(01)00173-3"/>
</citation>
<scope>INTERACTION WITH FANCD2</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2002" name="Cancer Res." volume="62" first="4588" last="4591">
<title>Phosphorylation of serine 1387 in BRCA1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.</title>
<authorList>
<person name="Xu B."/>
<person name="O'Donnell A.H."/>
<person name="Kim S.-T."/>
<person name="Kastan M.B."/>
</authorList>
<dbReference type="PubMed" id="12183412"/>
</citation>
<scope>PHOSPHORYLATION BY ATM</scope>
<scope>MUTAGENESIS OF SER-1387; SER-1423 AND SER-1524</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2002" name="Curr. Biol." volume="12" first="1846" last="1851">
<title>NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain.</title>
<authorList>
<person name="Kobayashi J."/>
<person name="Tauchi H."/>
<person name="Sakamoto S."/>
<person name="Nakamura A."/>
<person name="Morishima K."/>
<person name="Matsuura S."/>
<person name="Kobayashi T."/>
<person name="Tamai K."/>
<person name="Tanimoto K."/>
<person name="Komatsu K."/>
</authorList>
<dbReference type="PubMed" id="12419185"/>
<dbReference type="DOI" id="10.1016/S0960-9822(02)01259-9"/>
</citation>
<scope>INTERACTION WITH H2AFX</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2002" name="Genes Dev." volume="16" first="571" last="582">
<title>SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint.</title>
<authorList>
<person name="Yazdi P.T."/>
<person name="Wang Y."/>
<person name="Zhao S."/>
<person name="Patel N."/>
<person name="Lee E.Y.-H.P."/>
<person name="Qin J."/>
</authorList>
<dbReference type="PubMed" id="11877377"/>
<dbReference type="DOI" id="10.1101/gad.970702"/>
</citation>
<scope>INTERACTION WITH SMC1A</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="7849" last="7856">
<title>The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.</title>
<authorList>
<person name="Sum E.Y."/>
<person name="Peng B."/>
<person name="Yu X."/>
<person name="Chen J."/>
<person name="Byrne J."/>
<person name="Lindeman G.J."/>
<person name="Visvader J.E."/>
</authorList>
<dbReference type="PubMed" id="11751867"/>
<dbReference type="DOI" id="10.1074/jbc.M110603200"/>
</citation>
<scope>INTERACTION WITH LMO4</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2002" name="Nat. Genet." volume="30" first="285" last="289">
<title>BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.</title>
<authorList>
<person name="Yarden R.I."/>
<person name="Pardo-Reoyo S."/>
<person name="Sgagias M."/>
<person name="Cowan K.H."/>
<person name="Brody L.C."/>
</authorList>
<dbReference type="PubMed" id="11836499"/>
<dbReference type="DOI" id="10.1038/ng837"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH CHEK1</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Oncogene" volume="21" first="6729" last="6739">
<title>BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.</title>
<authorList>
<person name="Magnard C."/>
<person name="Bachelier R."/>
<person name="Vincent A."/>
<person name="Jaquinod M."/>
<person name="Kieffer S."/>
<person name="Lenoir G.M."/>
<person name="Venezia N.D."/>
</authorList>
<dbReference type="PubMed" id="12360400"/>
<dbReference type="DOI" id="10.1038/sj.onc.1205915"/>
</citation>
<scope>INTERACTION WITH ACACA</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="34743" last="34746">
<title>The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.</title>
<authorList>
<person name="Wu-Baer F."/>
<person name="Lagrazon K."/>
<person name="Yuan W."/>
<person name="Baer R."/>
</authorList>
<dbReference type="PubMed" id="12890688"/>
<dbReference type="DOI" id="10.1074/jbc.C300249200"/>
</citation>
<scope>FUNCTION</scope>
<scope>UBIQUITINATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH BARD1</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2003" name="Mol. Cell" volume="12" first="247" last="254">
<title>BRCA1-independent ubiquitination of FANCD2.</title>
<authorList>
<person name="Vandenberg C.J."/>
<person name="Gergely F."/>
<person name="Ong C.Y."/>
<person name="Pace P."/>
<person name="Mallery D.L."/>
<person name="Hiom K."/>
<person name="Patel K.J."/>
</authorList>
<dbReference type="PubMed" id="12887909"/>
<dbReference type="DOI" id="10.1016/S1097-2765(03)00281-8"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2003" name="Mol. Cell" volume="12" first="1087" last="1099">
<title>Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair.</title>
<authorList>
<person name="Dong Y."/>
<person name="Hakimi M.-A."/>
<person name="Chen X."/>
<person name="Kumaraswamy E."/>
<person name="Cooch N.S."/>
<person name="Godwin A.K."/>
<person name="Shiekhattar R."/>
</authorList>
<dbReference type="PubMed" id="14636569"/>
<dbReference type="DOI" id="10.1016/S1097-2765(03)00424-6"/>
</citation>
<scope>INTERACTION WITH BRCC3</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2004" name="Hum. Mol. Genet." volume="13" first="807" last="817">
<title>BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair.</title>
<authorList>
<person name="Morris J.R."/>
<person name="Solomon E."/>
</authorList>
<dbReference type="PubMed" id="14976165"/>
<dbReference type="DOI" id="10.1093/hmg/ddh095"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH BARD1</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="19643" last="19648">
<title>BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.</title>
<authorList>
<person name="Ouchi M."/>
<person name="Fujiuchi N."/>
<person name="Sasai K."/>
<person name="Katayama H."/>
<person name="Minamishima Y.A."/>
<person name="Ongusaha P.P."/>
<person name="Deng C."/>
<person name="Sen S."/>
<person name="Lee S.W."/>
<person name="Ouchi T."/>
</authorList>
<dbReference type="PubMed" id="14990569"/>
<dbReference type="DOI" id="10.1074/jbc.M311780200"/>
</citation>
<scope>INTERACTION WITH AURKA</scope>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF SER-308</scope>
<scope>PHOSPHORYLATION AT SER-308</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2004" name="Mol. Cell. Biol." volume="24" first="9207" last="9220">
<title>Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response.</title>
<authorList>
<person name="Zhang X."/>
<person name="Succi J."/>
<person name="Feng Z."/>
<person name="Prithivirajsingh S."/>
<person name="Story M.D."/>
<person name="Legerski R.J."/>
</authorList>
<dbReference type="PubMed" id="15456891"/>
<dbReference type="DOI" id="10.1128/MCB.24.20.9207-9220.2004"/>
</citation>
<scope>INTERACTION WITH DCLRE1C</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="Proc. Natl. Acad. Sci. U.S.A." volume="101" first="6484" last="6489">
<title>Human claspin works with BRCA1 to both positively and negatively regulate cell proliferation.</title>
<authorList>
<person name="Lin S.-Y."/>
<person name="Li K."/>
<person name="Stewart G.S."/>
<person name="Elledge S.J."/>
</authorList>
<dbReference type="PubMed" id="15096610"/>
<dbReference type="DOI" id="10.1073/pnas.0401847101"/>
</citation>
<scope>INTERACTION WITH CLSPN</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2006" name="Cell" volume="127" first="635" last="648">
<title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
<person name="Gnad F."/>
<person name="Macek B."/>
<person name="Kumar C."/>
<person name="Mortensen P."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="17081983"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.09.026"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1336</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="35">
<citation type="journal article" date="2006" name="Genes Dev." volume="20" first="1721" last="1726">
<title>BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.</title>
<authorList>
<person name="Yu X."/>
<person name="Fu S."/>
<person name="Lai M."/>
<person name="Baer R."/>
<person name="Chen J."/>
</authorList>
<dbReference type="PubMed" id="16818604"/>
<dbReference type="DOI" id="10.1101/gad.1431006"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH RBBP8</scope>
<scope>MUTAGENESIS OF ILE-26</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="3172" last="3181">
<title>BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.</title>
<authorList>
<person name="Moreau K."/>
<person name="Dizin E."/>
<person name="Ray H."/>
<person name="Luquain C."/>
<person name="Lefai E."/>
<person name="Foufelle F."/>
<person name="Billaud M."/>
<person name="Lenoir G.M."/>
<person name="Venezia N.D."/>
</authorList>
<dbReference type="PubMed" id="16326698"/>
<dbReference type="DOI" id="10.1074/jbc.M504652200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH ACACA</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2006" name="J. Mol. Biol." volume="359" first="973" last="982">
<title>ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.</title>
<authorList>
<person name="Ray H."/>
<person name="Moreau K."/>
<person name="Dizin E."/>
<person name="Callebaut I."/>
<person name="Venezia N.D."/>
</authorList>
<dbReference type="PubMed" id="16698035"/>
<dbReference type="DOI" id="10.1016/j.jmb.2006.04.010"/>
</citation>
<scope>INTERACTION WITH ACACA</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2007" name="Cancer Res." volume="67" first="11186" last="11194">
<title>Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation.</title>
<authorList>
<person name="Sankaran S."/>
<person name="Crone D.E."/>
<person name="Palazzo R.E."/>
<person name="Parvin J.D."/>
</authorList>
<dbReference type="PubMed" id="18056443"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-07-2578"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION BY AURKA</scope>
<scope>ACTIVITY REGULATION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2007" name="Nat. Struct. Mol. Biol." volume="14" first="710" last="715">
<title>CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response.</title>
<authorList>
<person name="Kim H."/>
<person name="Huang J."/>
<person name="Chen J."/>
</authorList>
<dbReference type="PubMed" id="17643122"/>
<dbReference type="DOI" id="10.1038/nsmb1277"/>
</citation>
<scope>INTERACTION WITH ABRAXAS1</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2007" name="Nat. Struct. Mol. Biol." volume="14" first="716" last="720">
<title>CCDC98 targets BRCA1 to DNA damage sites.</title>
<authorList>
<person name="Liu Z."/>
<person name="Wu J."/>
<person name="Yu X."/>
</authorList>
<dbReference type="PubMed" id="17643121"/>
<dbReference type="DOI" id="10.1038/nsmb1279"/>
</citation>
<scope>INTERACTION WITH ABRAXAS1</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2007" name="Science" volume="316" first="1160" last="1166">
<title>ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.</title>
<authorList>
<person name="Matsuoka S."/>
<person name="Ballif B.A."/>
<person name="Smogorzewska A."/>
<person name="McDonald E.R. III"/>
<person name="Hurov K.E."/>
<person name="Luo J."/>
<person name="Bakalarski C.E."/>
<person name="Zhao Z."/>
<person name="Solimini N."/>
<person name="Lerenthal Y."/>
<person name="Shiloh Y."/>
<person name="Gygi S.P."/>
<person name="Elledge S.J."/>
</authorList>
<dbReference type="PubMed" id="17525332"/>
<dbReference type="DOI" id="10.1126/science.1140321"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Embryonic kidney</tissue>
</source>
</reference>
<reference key="42">
<citation type="journal article" date="2007" name="Science" volume="316" first="1194" last="1198">
<title>Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.</title>
<authorList>
<person name="Wang B."/>
<person name="Matsuoka S."/>
<person name="Ballif B.A."/>
<person name="Zhang D."/>
<person name="Smogorzewska A."/>
<person name="Giyi S."/>
<person name="Elledge S.J."/>
</authorList>
<dbReference type="PubMed" id="17525340"/>
<dbReference type="DOI" id="10.1126/science.1139476"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH ABRAXAS1</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2008" name="Hum. Genet." volume="124" first="271" last="278">
<title>Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.</title>
<authorList>
<person name="Al-Sukhni W."/>
<person name="Rothenmund H."/>
<person name="Borgida A.E."/>
<person name="Zogopoulos G."/>
<person name="O'Shea A.M."/>
<person name="Pollett A."/>
<person name="Gallinger S."/>
</authorList>
<dbReference type="PubMed" id="18762988"/>
<dbReference type="DOI" id="10.1007/s00439-008-0554-0"/>
</citation>
<scope>INVOLVEMENT IN PNCA4</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-395; SER-398; SER-753; SER-1211; SER-1217 AND SER-1218</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="45">
<citation type="journal article" date="2009" name="Genes Dev." volume="23" first="719" last="728">
<title>MERIT40 facilitates BRCA1 localization and DNA damage repair.</title>
<authorList>
<person name="Feng L."/>
<person name="Huang J."/>
<person name="Chen J."/>
</authorList>
<dbReference type="PubMed" id="19261748"/>
<dbReference type="DOI" id="10.1101/gad.1770609"/>
</citation>
<scope>FUNCTION</scope>
<scope>IDENTIFICATION IN THE BRCA1-A COMPLEX</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2009" name="Genes Dev." volume="23" first="729" last="739">
<title>NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control.</title>
<authorList>
<person name="Wang B."/>
<person name="Hurov K."/>
<person name="Hofmann K."/>
<person name="Elledge S.J."/>
</authorList>
<dbReference type="PubMed" id="19261749"/>
<dbReference type="DOI" id="10.1101/gad.1770309"/>
</citation>
<scope>IDENTIFICATION IN THE BRCA1-A COMPLEX</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2009" name="Genes Dev." volume="23" first="740" last="754">
<title>MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.</title>
<authorList>
<person name="Shao G."/>
<person name="Patterson-Fortin J."/>
<person name="Messick T.E."/>
<person name="Feng D."/>
<person name="Shanbhag N."/>
<person name="Wang Y."/>
<person name="Greenberg R.A."/>
</authorList>
<dbReference type="PubMed" id="19261746"/>
<dbReference type="DOI" id="10.1101/gad.1739609"/>
</citation>
<scope>IDENTIFICATION IN THE BRCA1-A COMPLEX</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2009" name="Proc. Natl. Acad. Sci. U.S.A." volume="106" first="7155" last="7160">
<title>PALB2 is an integral component of the BRCA complex required for homologous recombination repair.</title>
<authorList>
<person name="Sy S.M."/>
<person name="Huen M.S."/>
<person name="Chen J."/>
</authorList>
<dbReference type="PubMed" id="19369211"/>
<dbReference type="DOI" id="10.1073/pnas.0811159106"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PALB2</scope>
<scope>IDENTIFICATION IN A BRCA COMPLEX WITH BRCA1 AND PALB2</scope>
<scope>CHARACTERIZATION OF VARIANT OVARIAN CANCER 1411-THR</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-395 AND SER-398</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="50">
<citation type="journal article" date="2010" name="Br. J. Cancer" volume="102" first="1061" last="1067">
<title>Identification of DBC1 as a transcriptional repressor for BRCA1.</title>
<authorList>
<person name="Hiraike H."/>
<person name="Wada-Hiraike O."/>
<person name="Nakagawa S."/>
<person name="Koyama S."/>
<person name="Miyamoto Y."/>
<person name="Sone K."/>
<person name="Tanikawa M."/>
<person name="Tsuruga T."/>
<person name="Nagasaka K."/>
<person name="Matsumoto Y."/>
<person name="Oda K."/>
<person name="Shoji K."/>
<person name="Fukuhara H."/>
<person name="Saji S."/>
<person name="Nakagawa K."/>
<person name="Kato S."/>
<person name="Yano T."/>
<person name="Taketani Y."/>
</authorList>
<dbReference type="PubMed" id="20160719"/>
<dbReference type="DOI" id="10.1038/sj.bjc.6605577"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH CCAR2</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2010" name="Mol. Cell. Biol." volume="30" first="2787" last="2798">
<title>The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.</title>
<authorList>
<person name="Wu-Baer F."/>
<person name="Ludwig T."/>
<person name="Baer R."/>
</authorList>
<dbReference type="PubMed" id="20351172"/>
<dbReference type="DOI" id="10.1128/MCB.01056-09"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH BARD1 AND UBXN1</scope>
<scope>UBIQUITINATION</scope>
<scope>MUTAGENESIS OF ILE-26</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2010" name="Nat. Cell Biol." volume="12" first="492" last="499">
<title>The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.</title>
<authorList>
<person name="Stolz A."/>
<person name="Ertych N."/>
<person name="Kienitz A."/>
<person name="Vogel C."/>
<person name="Schneider V."/>
<person name="Fritz B."/>
<person name="Jacob R."/>
<person name="Dittmar G."/>
<person name="Weichert W."/>
<person name="Petersen I."/>
<person name="Bastians H."/>
</authorList>
<dbReference type="PubMed" id="20364141"/>
<dbReference type="DOI" id="10.1038/ncb2051"/>
</citation>
<scope>FUNCTION IN CHROMOSOMAL STABILITY</scope>
<scope>PHOSPHORYLATION AT SER-988 BY CHEK2</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-423; SER-694; SER-1328; SER-1336 AND SER-1342</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="54">
<citation type="journal article" date="2011" name="Biochem. Biophys. Res. Commun." volume="404" first="476" last="481">
<title>Protein phosphatase 5 is necessary for ATR-mediated DNA repair.</title>
<authorList>
<person name="Kang Y."/>
<person name="Cheong H.M."/>
<person name="Lee J.H."/>
<person name="Song P.I."/>
<person name="Lee K.H."/>
<person name="Kim S.Y."/>
<person name="Jun J.Y."/>
<person name="You H.J."/>
</authorList>
<dbReference type="PubMed" id="21144835"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2010.12.005"/>
</citation>
<scope>PHOSPHORYLATION AT SER-1524</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2011" name="Mol. Cancer Res." volume="9" first="1091" last="1099">
<title>KIAA0101 interacts with BRCA1 and regulates centrosome number.</title>
<authorList>
<person name="Kais Z."/>
<person name="Barsky S.H."/>
<person name="Mathsyaraja H."/>
<person name="Zha A."/>
<person name="Ransburgh D.J."/>
<person name="He G."/>
<person name="Pilarski R.T."/>
<person name="Shapiro C.L."/>
<person name="Huang K."/>
<person name="Parvin J.D."/>
</authorList>
<dbReference type="PubMed" id="21673012"/>
<dbReference type="DOI" id="10.1158/1541-7786.MCR-10-0503"/>
</citation>
<scope>INTERACTION WITH PCLAF</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-1218; SER-1336 AND SER-1342</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2012" name="Proc. Natl. Acad. Sci. U.S.A." volume="109" first="12449" last="12454">
<title>N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.</title>
<authorList>
<person name="Van Damme P."/>
<person name="Lasa M."/>
<person name="Polevoda B."/>
<person name="Gazquez C."/>
<person name="Elosegui-Artola A."/>
<person name="Kim D.S."/>
<person name="De Juan-Pardo E."/>
<person name="Demeyer K."/>
<person name="Hole K."/>
<person name="Larrea E."/>
<person name="Timmerman E."/>
<person name="Prieto J."/>
<person name="Arnesen T."/>
<person name="Sherman F."/>
<person name="Gevaert K."/>
<person name="Aldabe R."/>
</authorList>
<dbReference type="PubMed" id="22814378"/>
<dbReference type="DOI" id="10.1073/pnas.1210303109"/>
</citation>
<scope>ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-434; SER-551; SER-694; SER-708; SER-1009; SER-1189; SER-1191 AND SER-1542</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="59">
<citation type="journal article" date="2014" name="Nat. Struct. Mol. Biol." volume="21" first="927" last="936">
<title>Uncovering global SUMOylation signaling networks in a site-specific manner.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="D'Souza R.C."/>
<person name="Yang B."/>
<person name="Verlaan-de Vries M."/>
<person name="Mann M."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25218447"/>
<dbReference type="DOI" id="10.1038/nsmb.2890"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-339; LYS-459; LYS-583; LYS-654; LYS-734 AND LYS-739</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2015" name="Mol. Cell. Proteomics" volume="14" first="1419" last="1434">
<title>System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.</title>
<authorList>
<person name="Xiao Z."/>
<person name="Chang J.G."/>
<person name="Hendriks I.A."/>
<person name="Sigurdsson J.O."/>
<person name="Olsen J.V."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25755297"/>
<dbReference type="DOI" id="10.1074/mcp.O114.044792"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-339; LYS-443 AND LYS-583</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="61">
<citation type="journal article" date="2016" name="Nat. Cell Biol." volume="18" first="271" last="280">
<title>EXD2 promotes homologous recombination by facilitating DNA end resection.</title>
<authorList>
<person name="Broderick R."/>
<person name="Nieminuszczy J."/>
<person name="Baddock H.T."/>
<person name="Deshpande R.A."/>
<person name="Gileadi O."/>
<person name="Paull T.T."/>
<person name="McHugh P.J."/>
<person name="Niedzwiedz W."/>
</authorList>
<dbReference type="PubMed" id="26807646"/>
<dbReference type="DOI" id="10.1038/ncb3303"/>
</citation>
<scope>INTERACTION WITH EXD2</scope>
</reference>
<reference key="62">
<citation type="journal article" date="2017" name="Nat. Struct. Mol. Biol." volume="24" first="325" last="336">
<title>Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="Lyon D."/>
<person name="Young C."/>
<person name="Jensen L.J."/>
<person name="Vertegaal A.C."/>
<person name="Nielsen M.L."/>
</authorList>
<dbReference type="PubMed" id="28112733"/>
<dbReference type="DOI" id="10.1038/nsmb.3366"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-109; LYS-301; LYS-339; LYS-443; LYS-459; LYS-519; LYS-583; LYS-918; LYS-987 AND LYS-1079</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="63">
<citation type="journal article" date="2017" name="Oncogene" volume="36" first="4161" last="4170">
<title>Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.</title>
<authorList>
<person name="Foo T.K."/>
<person name="Tischkowitz M."/>
<person name="Simhadri S."/>
<person name="Boshari T."/>
<person name="Zayed N."/>
<person name="Burke K.A."/>
<person name="Berman S.H."/>
<person name="Blecua P."/>
<person name="Riaz N."/>
<person name="Huo Y."/>
<person name="Ding Y.C."/>
<person name="Neuhausen S.L."/>
<person name="Weigelt B."/>
<person name="Reis-Filho J.S."/>
<person name="Foulkes W.D."/>
<person name="Xia B."/>
</authorList>
<dbReference type="PubMed" id="28319063"/>
<dbReference type="DOI" id="10.1038/onc.2017.46"/>
</citation>
<scope>INTERACTION WITH PALB2</scope>
</reference>
<reference key="64">
<citation type="journal article" date="2001" name="Nat. Struct. Biol." volume="8" first="833" last="837">
<title>Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.</title>
<authorList>
<person name="Brzovic P.S."/>
<person name="Rajagopal P."/>
<person name="Hoyt D.W."/>
<person name="King M.C."/>
<person name="Klevit R.E."/>
</authorList>
<dbReference type="PubMed" id="11573085"/>
<dbReference type="DOI" id="10.1038/nsb1001-833"/>
</citation>
<scope>STRUCTURE BY NMR OF 1-110 IN COMPLEX WITH ZINC IONS AND BARD1</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="65">
<citation type="journal article" date="2001" name="Nat. Struct. Biol." volume="8" first="838" last="842">
<title>Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.</title>
<authorList>
<person name="Williams R.S."/>
<person name="Green R."/>
<person name="Glover J.N."/>
</authorList>
<dbReference type="PubMed" id="11573086"/>
<dbReference type="DOI" id="10.1038/nsb1001-838"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1646-1859</scope>
<scope>PARTIAL PROTEIN SEQUENCE</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="66">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="2630" last="2635">
<title>Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.</title>
<authorList>
<person name="Williams R.S."/>
<person name="Glover J.N."/>
</authorList>
<dbReference type="PubMed" id="12427738"/>
<dbReference type="DOI" id="10.1074/jbc.M210019200"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1646-1859 OF VARIANT BC ARG-1775</scope>
<scope>CHARACTERIZATION OF VARIANT BC ARG-1775</scope>
<scope>CIRCULAR DICHROISM</scope>
</reference>
<reference key="67">
<citation type="journal article" date="2004" name="Biochemistry" volume="43" first="15983" last="15995">
<title>Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.</title>
<authorList>
<person name="Gaiser O.J."/>
<person name="Ball L.J."/>
<person name="Schmieder P."/>
<person name="Leitner D."/>
<person name="Strauss H."/>
<person name="Wahl M."/>
<person name="Kuhne R."/>
<person name="Oschkinat H."/>
<person name="Heinemann U."/>
</authorList>
<dbReference type="PubMed" id="15609993"/>
<dbReference type="DOI" id="10.1021/bi049550q"/>
</citation>
<scope>STRUCTURE BY NMR OF 1755-1863</scope>
</reference>
<reference key="68">
<citation type="journal article" date="2004" name="Nat. Struct. Mol. Biol." volume="11" first="512" last="518">
<title>Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.</title>
<authorList>
<person name="Clapperton J.A."/>
<person name="Manke I.A."/>
<person name="Lowery D.M."/>
<person name="Ho T."/>
<person name="Haire L.F."/>
<person name="Yaffe M.B."/>
<person name="Smerdon S.J."/>
</authorList>
<dbReference type="PubMed" id="15133502"/>
<dbReference type="DOI" id="10.1038/nsmb775"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1649-1859 IN COMPLEX WITH PHOSPHORYLATED BRIP1 PEPTIDE</scope>
<scope>MUTAGENESIS OF SER-1655; LYS-1702 AND GLY-1738</scope>
<scope>CHARACTERIZATION OF VARIANT OVARIAN CANCER ARG-1749</scope>
<scope>CHARACTERIZATION OF VARIANT BC ARG-1775</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH PHOSPHORYLATED BRIP1</scope>
</reference>
<reference key="69">
<citation type="journal article" date="2005" name="Biochemistry" volume="44" first="10941" last="10946">
<title>Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.</title>
<authorList>
<person name="Varma A.K."/>
<person name="Brown R.S."/>
<person name="Birrane G."/>
<person name="Ladias J.A."/>
</authorList>
<dbReference type="PubMed" id="16101277"/>
<dbReference type="DOI" id="10.1021/bi0509651"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1646-1859 IN COMPLEX WITH PHOSPHORYLATED RBBP8 PEPTIDE</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="70">
<citation type="journal article" date="2008" name="Biochemistry" volume="47" first="5767" last="5773">
<title>Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.</title>
<authorList>
<person name="Shen Y."/>
<person name="Tong L."/>
</authorList>
<dbReference type="PubMed" id="18452305"/>
<dbReference type="DOI" id="10.1021/bi800314m"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.21 ANGSTROMS) OF 1646-1859 IN COMPLEX WITH PHOSPHORYLATED ACACA PEPTIDE</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="71">
<citation type="journal article" date="2008" name="Eur. J. Hum. Genet." volume="16" first="820" last="832">
<title>Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.</title>
<authorList>
<person name="Tischkowitz M."/>
<person name="Hamel N."/>
<person name="Carvalho M.A."/>
<person name="Birrane G."/>
<person name="Soni A."/>
<person name="van Beers E.H."/>
<person name="Joosse S.A."/>
<person name="Wong N."/>
<person name="Novak D."/>
<person name="Quenneville L.A."/>
<person name="Grist S.A."/>
<person name="Nederlof P.M."/>
<person name="Goldgar D.E."/>
<person name="Tavtigian S.V."/>
<person name="Monteiro A.N."/>
<person name="Ladias J.A."/>
<person name="Foulkes W.D."/>
</authorList>
<dbReference type="PubMed" id="18285836"/>
<dbReference type="DOI" id="10.1038/ejhg.2008.13"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.6 ANGSTROMS) OF 1649-1859 OF VARIANT BC LYS-1775</scope>
<scope>VARIANT BC LYS-1775</scope>
<scope>CHARACTERIZATION OF VARIANT BC LYS-1775</scope>
</reference>
<reference key="72">
<citation type="journal article" date="2010" name="Structure" volume="18" first="167" last="176">
<title>Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1.</title>
<authorList>
<person name="Campbell S.J."/>
<person name="Edwards R.A."/>
<person name="Glover J.N."/>
</authorList>
<dbReference type="PubMed" id="20159462"/>
<dbReference type="DOI" id="10.1016/j.str.2009.12.008"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1646-1859 IN COMPLEX WITH PHOSPHORYLATED PEPTIDES</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="73">
<citation type="journal article" date="2011" name="Biochemistry" volume="50" first="4579" last="4589">
<title>Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.</title>
<authorList>
<person name="Coquelle N."/>
<person name="Green R."/>
<person name="Glover J.N."/>
</authorList>
<dbReference type="PubMed" id="21473589"/>
<dbReference type="DOI" id="10.1021/bi2003795"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1646-1859 IN COMPLEX WITH PHOSPHORYLATED BRIP1 PEPTIDE</scope>
<scope>INTERACTION WITH BRIP1</scope>
<scope>MUTAGENESIS OF GLY-1656; THR-1700; ARG-1835 AND GLU-1836</scope>
<scope>CHARACTERIZATION OF VARIANTS BC GLN-1699 AND TRP-1699</scope>
</reference>
<reference key="74">
<citation type="journal article" date="2013" name="Acta Crystallogr. F" volume="69" first="1401" last="1404">
<title>Preliminary crystallographic studies of BRCA1 BRCT-ABRAXAS complex.</title>
<authorList>
<person name="Badgujar D.C."/>
<person name="Sawant U."/>
<person name="Vikrant X."/>
<person name="Yadav L."/>
<person name="Hosur M.V."/>
<person name="Varma A.K."/>
</authorList>
<dbReference type="PubMed" id="24316840"/>
<dbReference type="DOI" id="10.1107/S1744309113030649"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 1649-1859 IN COMPLEX WITH ABRAXAS1</scope>
<scope>INTERACTION WITH ABRAXAS1</scope>
</reference>
<reference key="75">
<citation type="journal article" date="2016" name="Mol. Cell" volume="61" first="434" last="448">
<title>Structure of BRCA1-BRCT/Abraxas complex reveals phosphorylation-dependent BRCT dimerization at DNA damage sites.</title>
<authorList>
<person name="Wu Q."/>
<person name="Paul A."/>
<person name="Su D."/>
<person name="Mehmood S."/>
<person name="Foo T.K."/>
<person name="Ochi T."/>
<person name="Bunting E.L."/>
<person name="Xia B."/>
<person name="Robinson C.V."/>
<person name="Wang B."/>
<person name="Blundell T.L."/>
</authorList>
<dbReference type="PubMed" id="26778126"/>
<dbReference type="DOI" id="10.1016/j.molcel.2015.12.017"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1646-1859 IN COMPLEX WITH ABRAXAS1</scope>
<scope>INTERACTION WITH ABRAXAS1</scope>
<scope>SUBUNIT</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>MUTAGENESIS OF PHE-1662; MET-1663; TYR-1666; ARG-1670 AND LYS-1671</scope>
</reference>
<reference key="76">
<citation type="journal article" date="1996" name="Hum. Mutat." volume="8" first="8" last="18">
<title>Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene.</title>
<authorList>
<person name="Couch F.J."/>
<person name="Weber B.L."/>
</authorList>
<dbReference type="PubMed" id="8807330"/>
<dbReference type="DOI" id="10.1002/humu.1380080102"/>
</citation>
<scope>REVIEW ON VARIANTS</scope>
</reference>
<reference key="77">
<citation type="journal article" date="1994" name="Science" volume="266" first="120" last="122">
<title>BRCA1 mutations in primary breast and ovarian carcinomas.</title>
<authorList>
<person name="Futreal P.A."/>
<person name="Liu Q."/>
<person name="Shattuck-Eidens D."/>
<person name="Cochran C."/>
<person name="Harshman K."/>
<person name="Tavtigian S."/>
<person name="Bennett L.M."/>
<person name="Haugen-Strano A."/>
<person name="Swensen J."/>
<person name="Miki Y."/>
<person name="Eddington K."/>
<person name="McClure M."/>
<person name="Frye C."/>
<person name="Weaver-Felhaus J."/>
<person name="Ding W."/>
<person name="Gholami Z."/>
<person name="Soederkvist P."/>
<person name="Terry L."/>
<person name="Jhanwar S."/>
<person name="Berchuk A."/>
<person name="Iglehart J.D."/>
<person name="Marks J."/>
<person name="Ballinger D.G."/>
<person name="Barrett J.C."/>
<person name="Skolnick M.H."/>
<person name="Kamb A."/>
<person name="Wiseman R."/>
</authorList>
<dbReference type="PubMed" id="7939630"/>
<dbReference type="DOI" id="10.1126/science.7939630"/>
</citation>
<scope>VARIANT BC ARG-1775</scope>
<scope>VARIANTS LEU-1637 AND GLU-1708</scope>
</reference>
<reference key="78">
<citation type="journal article" date="1994" name="Nat. Genet." volume="8" first="387" last="391">
<title>Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.</title>
<authorList>
<person name="Castilla L.H."/>
<person name="Couch F.J."/>
<person name="Erdos M.R."/>
<person name="Hoskins K.F."/>
<person name="Calzone K."/>
<person name="Garber J.E."/>
<person name="Boyd J."/>
<person name="Lubin M.B."/>
<person name="Deshano M.L."/>
<person name="Brody L.C."/>
<person name="Collins F.S."/>
<person name="Weber B.L."/>
</authorList>
<dbReference type="PubMed" id="7894491"/>
<dbReference type="DOI" id="10.1038/ng1294-387"/>
</citation>
<scope>VARIANT BC GLY-64</scope>
<scope>VARIANTS ALA-772; ASN-1040 AND GLY-1443</scope>
</reference>
<reference key="79">
<citation type="journal article" date="1994" name="Nat. Genet." volume="8" first="399" last="404">
<title>Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.</title>
<authorList>
<person name="Friedman L.S."/>
<person name="Ostermeyer E.A."/>
<person name="Szabo C.I."/>
<person name="Dowd P."/>
<person name="Lynch E.D."/>
<person name="Rowell S.E."/>
<person name="King M.-C."/>
</authorList>
<dbReference type="PubMed" id="7894493"/>
<dbReference type="DOI" id="10.1038/ng1294-399"/>
</citation>
<scope>VARIANT BC GLY-61</scope>
<scope>VARIANTS ARG-356; GLY-1038; ASN-1040; ARG-1183 AND GLY-1613</scope>
</reference>
<reference key="80">
<citation type="journal article" date="1996" name="Am. J. Hum. Genet." volume="58" first="42" last="51">
<title>A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.</title>
<authorList>
<person name="Serova O."/>
<person name="Montagna M."/>
<person name="Torchard D."/>
<person name="Narod S.A."/>
<person name="Tonin P."/>
<person name="Sylla B."/>
<person name="Lynch H.T."/>
<person name="Feunteun J."/>
<person name="Lenoir G.M."/>
</authorList>
<dbReference type="PubMed" id="8554067"/>
</citation>
<scope>VARIANT BC GLY-61</scope>
</reference>
<reference key="81">
<citation type="journal article" date="1996" name="Genet. Epidemiol." volume="13" first="595" last="604">
<title>BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.</title>
<authorList>
<person name="Barker D.F."/>
<person name="Almeida E.F.A."/>
<person name="Casey G."/>
<person name="Fain P.R."/>
<person name="Liao S.-Y."/>
<person name="Masunaka I."/>
<person name="Noble B."/>
<person name="Kurosaki T."/>
<person name="Anton-Culver H."/>
</authorList>
<dbReference type="PubMed" id="8968716"/>
<dbReference type="DOI" id="10.1002/(SICI)1098-2272(1996)13:6&lt;595::AID-GEPI5&gt;3.3.CO;2-0"/>
</citation>
<scope>VARIANT BROVCA1 TRP-841</scope>
</reference>
<reference key="82">
<citation type="journal article" date="1996" name="Hum. Mol. Genet." volume="5" first="835" last="842">
<title>Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.</title>
<authorList>
<person name="Durocher F."/>
<person name="Shattuck-Eidens D."/>
<person name="McClure M."/>
<person name="Labrie F."/>
<person name="Skolnick M.H."/>
<person name="Goldgar D.E."/>
<person name="Simard J."/>
</authorList>
<dbReference type="PubMed" id="8776600"/>
<dbReference type="DOI" id="10.1093/hmg/5.6.835"/>
</citation>
<scope>VARIANTS BC AND BROVCA1</scope>
</reference>
<reference key="83">
<citation type="journal article" date="1996" name="Hum. Mutat." volume="7" first="334" last="339">
<title>Mutations in the BRCA1 gene in Japanese breast cancer patients.</title>
<authorList>
<person name="Katagiri T."/>
<person name="Emi M."/>
<person name="Ito I."/>
<person name="Kobayashi K."/>
<person name="Yoshimoto M."/>
<person name="Iwase T."/>
<person name="Kasumi F."/>
<person name="Miki Y."/>
<person name="Skolnick M.H."/>
<person name="Nakamura Y."/>
</authorList>
<dbReference type="PubMed" id="8723683"/>
<dbReference type="DOI" id="10.1002/(SICI)1098-1004(1996)7:4&lt;334::AID-HUMU7&gt;3.3.CO;2-K"/>
</citation>
<scope>VARIANTS BC MET-271 AND SER-1150</scope>
</reference>
<reference key="84">
<citation type="journal article" date="1998" name="Hum. Genet." volume="103" first="154" last="161">
<title>A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.</title>
<authorList>
<person name="Dong J."/>
<person name="Chang-Claude J."/>
<person name="Wu Y."/>
<person name="Schumacher V."/>
<person name="Debatin I."/>
<person name="Tonin P."/>
<person name="Royer-Pokora B."/>
</authorList>
<dbReference type="PubMed" id="9760198"/>
<dbReference type="DOI" id="10.1007/s004390050799"/>
</citation>
<scope>VARIANT BC GLY-61</scope>
<scope>VARIANTS ARG-239; TRP-841 AND ILE-1512</scope>
</reference>
<reference key="85">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="11" first="166" last="174">
<title>Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.</title>
<authorList>
<person name="Andersen T.I."/>
<person name="Eiken H.G."/>
<person name="Couch F."/>
<person name="Kaada G."/>
<person name="Skrede M."/>
<person name="Johnsen H."/>
<person name="Aloysius T.A."/>
<person name="Tveit K.M."/>
<person name="Tranebjaerg L."/>
<person name="Doerum A."/>
<person name="Moeller P."/>
<person name="Weber B.L."/>
<person name="Boerresen-Dale A.-L."/>
</authorList>
<dbReference type="PubMed" id="9482581"/>
<dbReference type="DOI" id="10.1002/(SICI)1098-1004(1998)11:2&lt;166::AID-HUMU10&gt;3.0.CO;2-X"/>
</citation>
<scope>VARIANT BC GLY-64</scope>
<scope>VARIANTS ALA-772; GLU-820; ASN-1040; GLY-1443; ILE-1512; LEU-1637 AND ILE-1652</scope>
</reference>
<reference key="86">
<citation type="journal article" date="1998" name="J. Hum. Genet." volume="43" first="42" last="48">
<title>High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.</title>
<authorList>
<person name="Katagiri T."/>
<person name="Kasumi F."/>
<person name="Yoshimoto M."/>
<person name="Nomizu T."/>
<person name="Asaishi K."/>
<person name="Abe R."/>
<person name="Tsuchiya A."/>
<person name="Sugano M."/>
<person name="Takai S."/>
<person name="Yoneda M."/>
<person name="Fukutomi T."/>
<person name="Nanba K."/>
<person name="Makita M."/>
<person name="Okazaki H."/>
<person name="Hirata K."/>
<person name="Okazaki M."/>
<person name="Furutsuma Y."/>
<person name="Morishita Y."/>
<person name="Iino Y."/>
<person name="Karino T."/>
<person name="Ayabe H."/>
<person name="Hara S."/>
<person name="Kajiwara T."/>
<person name="Houga S."/>
<person name="Shimizu T."/>
<person name="Toda M."/>
<person name="Yamazaki Y."/>
<person name="Uchida T."/>
<person name="Kunitomo K."/>
<person name="Sonoo H."/>
<person name="Kurebayashi J."/>
<person name="Shimotsuma K."/>
<person name="Nakamura Y."/>
<person name="Miki Y."/>
</authorList>
<dbReference type="PubMed" id="9609997"/>
<dbReference type="DOI" id="10.1007/s100380050035"/>
</citation>
<scope>VARIANTS BC SER-22; LEU-461; ASP-465; VAL-552; SER-892; ASP-960; ILE-1025 AND ALA-1047</scope>
</reference>
<reference key="87">
<citation type="journal article" date="1999" name="Am. J. Hum. Genet." volume="65" first="1021" last="1029">
<title>The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.</title>
<authorList>
<person name="Gayther S.A."/>
<person name="Russell P."/>
<person name="Harrington P."/>
<person name="Antoniou A.C."/>
<person name="Easton D.F."/>
<person name="Ponder B.A.J."/>
</authorList>
<dbReference type="PubMed" id="10486320"/>
<dbReference type="DOI" id="10.1086/302583"/>
</citation>
<scope>VARIANT OVARIAN CANCER ARG-1749</scope>
</reference>
<reference key="88">
<citation type="journal article" date="1999" name="Hum. Genet." volume="104" first="201" last="204">
<title>Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.</title>
<authorList>
<person name="Li S.S.-L."/>
<person name="Tseng H.-M."/>
<person name="Yang T.-P."/>
<person name="Liu C.-H."/>
<person name="Teng S.-J."/>
<person name="Huang H.-W."/>
<person name="Chen L.-M."/>
<person name="Kao H.-W."/>
<person name="Chen J.H."/>
<person name="Tseng J.-N."/>
<person name="Chen A."/>
<person name="Hou M.-F."/>
<person name="Huang T.-J."/>
<person name="Chang H.-T."/>
<person name="Mok K.-T."/>
<person name="Tsai J.-H."/>
</authorList>
<dbReference type="PubMed" id="10323242"/>
<dbReference type="DOI" id="10.1007/s004390050936"/>
</citation>
<scope>VARIANT BC SER-346</scope>
<scope>VARIANTS LEU-871; GLY-1038; ARG-1183 AND GLY-1613</scope>
</reference>
<reference key="89">
<citation type="journal article" date="1999" name="Hum. Mol. Genet." volume="8" first="889" last="897">
<title>Germline BRCA1 alterations in a population-based series of ovarian cancer cases.</title>
<authorList>
<person name="Janezic S.A."/>
<person name="Ziogas A."/>
<person name="Krumroy L.M."/>
<person name="Krasner M."/>
<person name="Plummer S.J."/>
<person name="Cohen P."/>
<person name="Gildea M."/>
<person name="Barker D."/>
<person name="Haile R."/>
<person name="Casey G."/>
<person name="Anton-Culver H."/>
</authorList>
<dbReference type="PubMed" id="10196379"/>
<dbReference type="DOI" id="10.1093/hmg/8.5.889"/>
</citation>
<scope>VARIANTS OVARIAN CANCER</scope>
<scope>VARIANTS</scope>
</reference>
<reference key="90">
<citation type="journal article" date="2002" name="Genet. Test." volume="6" first="119" last="121">
<title>Characterization of common BRCA1 and BRCA2 variants.</title>
<authorList>
<person name="Deffenbaugh A.M."/>
<person name="Frank T.S."/>
<person name="Hoffman M."/>
<person name="Cannon-Albright L."/>
<person name="Neuhausen S.L."/>
</authorList>
<dbReference type="PubMed" id="12215251"/>
<dbReference type="DOI" id="10.1089/10906570260199375"/>
</citation>
<scope>VARIANTS GLY-1347; ILE-1512 AND ILE-1652</scope>
</reference>
<reference key="91">
<citation type="journal article" date="2002" name="Hum. Mutat." volume="20" first="474" last="474">
<title>BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.</title>
<authorList>
<person name="Zhi X."/>
<person name="Szabo C."/>
<person name="Chopin S."/>
<person name="Suter N."/>
<person name="Wang Q.-S."/>
<person name="Ostrander E.A."/>
<person name="Sinilnikova O.M."/>
<person name="Lenoir G.M."/>
<person name="Goldgar D."/>
<person name="Shi Y.-R."/>
</authorList>
<dbReference type="PubMed" id="12442274"/>
<dbReference type="DOI" id="10.1002/humu.9083"/>
</citation>
<scope>VARIANTS ILE-656; LEU-871 AND GLY-1613</scope>
</reference>
<reference key="92">
<citation type="journal article" date="2002" name="Hum. Mutat." volume="20" first="474" last="475">
<title>BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.</title>
<authorList>
<person name="Ruiz-Flores P."/>
<person name="Sinilnikova O.M."/>
<person name="Badzioch M."/>
<person name="Calderon-Garciduenas A.L."/>
<person name="Chopin S."/>
<person name="Fabrice O."/>
<person name="Gonzalez-Guerrero J.F."/>
<person name="Szabo C."/>
<person name="Lenoir G."/>
<person name="Goldgar D.E."/>
<person name="Barrera-Saldana H.A."/>
</authorList>
<dbReference type="PubMed" id="12442275"/>
<dbReference type="DOI" id="10.1002/humu.9084"/>
</citation>
<scope>VARIANT BC TYR-749</scope>
</reference>
<reference key="93">
<citation type="journal article" date="2003" name="Hum. Mutat." volume="22" first="259" last="259">
<title>Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.</title>
<authorList>
<person name="Meyer P."/>
<person name="Voigtlaender T."/>
<person name="Bartram C.R."/>
<person name="Klaes R."/>
</authorList>
<dbReference type="PubMed" id="12938098"/>
<dbReference type="DOI" id="10.1002/humu.9174"/>
</citation>
<scope>VARIANTS BC GLY-61; LYS-71; GLN-866; TYR-888; ILE-1139; GLY-1210 AND PRO-1297</scope>
<scope>VARIANTS BROVCA1 TYR-835 AND PRO-1786</scope>
</reference>
<reference key="94">
<citation type="journal article" date="2004" name="Br. J. Cancer" volume="90" first="1244" last="1251">
<title>BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.</title>
<authorList>
<person name="Claes K."/>
<person name="Poppe B."/>
<person name="Coene I."/>
<person name="De Paepe A."/>
<person name="Messiaen L."/>
</authorList>
<dbReference type="PubMed" id="15026808"/>
<dbReference type="DOI" id="10.1038/sj.bjc.6601656"/>
</citation>
<scope>VARIANTS ASN-693; ASN-1040; ALA-1060 AND MET-1665</scope>
</reference>
<reference key="95">
<citation type="journal article" date="2004" name="Eur. J. Cancer" volume="40" first="422" last="428">
<title>One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.</title>
<authorList>
<person name="Malander S."/>
<person name="Ridderheim M."/>
<person name="Masbaeck A."/>
<person name="Loman N."/>
<person name="Kristoffersson U."/>
<person name="Olsson H."/>
<person name="Nilbert M."/>
<person name="Borg A."/>
</authorList>
<dbReference type="PubMed" id="14746861"/>
<dbReference type="DOI" id="10.1016/j.ejca.2003.09.016"/>
</citation>
<scope>VARIANTS OVARIAN CANCER GLY-61; THR-1411; ARG-1697 AND TRP-1699</scope>
</reference>
<reference key="96">
<citation type="journal article" date="2004" name="Hum. Mutat." volume="23" first="205" last="205">
<title>Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.</title>
<authorList>
<person name="Valarmathi M.T."/>
<person name="Sawhney M."/>
<person name="Deo S.S.V."/>
<person name="Shukla N.K."/>
<person name="Das S.N."/>
</authorList>
<dbReference type="PubMed" id="14722926"/>
<dbReference type="DOI" id="10.1002/humu.9213"/>
</citation>
<scope>VARIANTS BC/BROVCA1 LYS-10; LYS-23; ILE-1187; HIS-1200 AND TYR-1217</scope>
<scope>VARIANTS BC ILE-1204 AND ASN-1207</scope>
<scope>VARIANTS BROVCA1 LEU-1226 AND GLY-1243</scope>
<scope>VARIANT ARG-1183</scope>
</reference>
<reference key="97">
<citation type="journal article" date="2004" name="Hum. Mutat." volume="24" first="350" last="350">
<title>BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.</title>
<authorList>
<person name="Seo J.H."/>
<person name="Cho D.-Y."/>
<person name="Ahn S.-H."/>
<person name="Yoon K.-S."/>
<person name="Kang C.-S."/>
<person name="Cho H.M."/>
<person name="Lee H.S."/>
<person name="Choe J.J."/>
<person name="Choi C.W."/>
<person name="Kim B.S."/>
<person name="Shin S.W."/>
<person name="Kim Y.H."/>
<person name="Kim J.S."/>
<person name="Son G.-S."/>
<person name="Lee J.-B."/>
<person name="Koo B.H."/>
</authorList>
<dbReference type="PubMed" id="15365993"/>
<dbReference type="DOI" id="10.1002/humu.9275"/>
</citation>
<scope>VARIANTS HIS-856; LEU-871; GLY-1038; ARG-1183; THR-1628; GLN-1690 AND GLY-1713</scope>
</reference>
<reference key="98">
<citation type="journal article" date="2006" name="Science" volume="314" first="268" last="274">
<title>The consensus coding sequences of human breast and colorectal cancers.</title>
<authorList>
<person name="Sjoeblom T."/>
<person name="Jones S."/>
<person name="Wood L.D."/>
<person name="Parsons D.W."/>
<person name="Lin J."/>
<person name="Barber T.D."/>
<person name="Mandelker D."/>
<person name="Leary R.J."/>
<person name="Ptak J."/>
<person name="Silliman N."/>
<person name="Szabo S."/>
<person name="Buckhaults P."/>
<person name="Farrell C."/>
<person name="Meeh P."/>
<person name="Markowitz S.D."/>
<person name="Willis J."/>
<person name="Dawson D."/>
<person name="Willson J.K.V."/>
<person name="Gazdar A.F."/>
<person name="Hartigan J."/>
<person name="Wu L."/>
<person name="Liu C."/>
<person name="Parmigiani G."/>
<person name="Park B.H."/>
<person name="Bachman K.E."/>
<person name="Papadopoulos N."/>
<person name="Vogelstein B."/>
<person name="Kinzler K.W."/>
<person name="Velculescu V.E."/>
</authorList>
<dbReference type="PubMed" id="16959974"/>
<dbReference type="DOI" id="10.1126/science.1133427"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] PHE-30; PHE-758 AND CYS-778</scope>
</reference>
<reference key="99">
<citation type="journal article" date="2007" name="Am. J. Hum. Genet." volume="81" first="873" last="883">
<title>A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.</title>
<authorList>
<person name="Easton D.F."/>
<person name="Deffenbaugh A.M."/>
<person name="Pruss D."/>
<person name="Frye C."/>
<person name="Wenstrup R.J."/>
<person name="Allen-Brady K."/>
<person name="Tavtigian S.V."/>
<person name="Monteiro A.N.A."/>
<person name="Iversen E.S."/>
<person name="Couch F.J."/>
<person name="Goldgar D.E."/>
</authorList>
<dbReference type="PubMed" id="17924331"/>
<dbReference type="DOI" id="10.1086/521032"/>
</citation>
<scope>VARIANTS THR-18; MET-1495; GLY-1623; ILE-1685; ALA-1685; ARG-1689; TRP-1699; GLU-1706; GLU-1708; ARG-1715; ARG-1738; PRO-1764; SER-1766 AND VAL-1788</scope>
</reference>
<reference key="100">
<citation type="journal article" date="2010" name="Hum. Mutat." volume="31" first="E1484" last="E1505">
<title>Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.</title>
<authorList>
<person name="Walker L.C."/>
<person name="Whiley P.J."/>
<person name="Couch F.J."/>
<person name="Farrugia D.J."/>
<person name="Healey S."/>
<person name="Eccles D.M."/>
<person name="Lin F."/>
<person name="Butler S.A."/>
<person name="Goff S.A."/>
<person name="Thompson B.A."/>
<person name="Lakhani S.R."/>
<person name="Da Silva L.M."/>
<person name="Tavtigian S.V."/>
<person name="Goldgar D.E."/>
<person name="Brown M.A."/>
<person name="Spurdle A.B."/>
</authorList>
<dbReference type="PubMed" id="20513136"/>
<dbReference type="DOI" id="10.1002/humu.21267"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS GLY-1623 AND ILE-1685</scope>
</reference>
<reference key="101">
<citation type="journal article" date="2013" name="Cancer Discov." volume="3" first="399" last="405">
<title>Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.</title>
<authorList>
<person name="Domchek S.M."/>
<person name="Tang J."/>
<person name="Stopfer J."/>
<person name="Lilli D.R."/>
<person name="Hamel N."/>
<person name="Tischkowitz M."/>
<person name="Monteiro A.N."/>
<person name="Messick T.E."/>
<person name="Powers J."/>
<person name="Yonker A."/>
<person name="Couch F.J."/>
<person name="Goldgar D.E."/>
<person name="Davidson H.R."/>
<person name="Nathanson K.L."/>
<person name="Foulkes W.D."/>
<person name="Greenberg R.A."/>
</authorList>
<dbReference type="PubMed" id="23269703"/>
<dbReference type="DOI" id="10.1158/2159-8290.CD-12-0421"/>
</citation>
<scope>VARIANT FANCS ALA-1736</scope>
<scope>CHARACTERIZATION OF VARIANT FANCS ALA-1736</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH UIMC1</scope>
</reference>
<reference key="102">
<citation type="journal article" date="2013" name="Cancer Discov." volume="3" first="1142" last="1155">
<title>A high-throughput functional complementation assay for classification of BRCA1 missense variants.</title>
<authorList>
<person name="Bouwman P."/>
<person name="van der Gulden H."/>
<person name="van der Heijden I."/>
<person name="Drost R."/>
<person name="Klijn C.N."/>
<person name="Prasetyanti P."/>
<person name="Pieterse M."/>
<person name="Wientjens E."/>
<person name="Seibler J."/>
<person name="Hogervorst F.B."/>
<person name="Jonkers J."/>
</authorList>
<dbReference type="PubMed" id="23867111"/>
<dbReference type="DOI" id="10.1158/2159-8290.CD-13-0094"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS BC PHE-4; THR-18; GLN-45; GLY-61; GLY-64; TYR-67; LYS-132; HIS-142; PHE-147; PRO-165; TRP-170; TYR-186; ILE-191; MET-231; VAL-245; VAL-246; LEU-271; PHE-668; ASN-695; LEU-798; TYR-810; LYS-826; GLN-841; HIS-856; ASN-1101; ASN-1140; GLY-1140; LYS-1214; LYS-1236; SER-1267; VAL-1282; SER-1297 DEL; ARG-1301; LYS-1346; ILE-1378; VAL-1400; PRO-1407; THR-1411; GLY-1443; GLY-1448; CYS-1486; MET-1534; PRO-1589; THR-1628; PRO-1651; PHE-1651; PHE-1655; ARG-1686; GLN-1686; VAL-1688 DEL; ILE-1691; TRP-1699; GLN-1699; GLU-1706; ALA-1706; GLU-1708; CYS-1718; ALA-1720; LYS-1735; ALA-1736; GLY-1739; VAL-1739; GLN-1746; THR-1753; PRO-1764; SER-1767; VAL-1770; CYS-1782; THR-1789; ASP-1794; ASP-1804; ARG-1812; ARG-1837 AND LEU-1862</scope>
<scope>VARIANTS CYS-105; CYS-866; ALA-1060; LYS-1250 AND ILE-1652</scope>
</reference>
<reference key="103">
<citation type="journal article" date="2015" name="Cancer Discov." volume="5" first="135" last="142">
<title>Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.</title>
<authorList>
<consortium name="University of Washington Centre for Mendelian Genomics"/>
<consortium name="FORGE Canada Consortium"/>
<person name="Sawyer S.L."/>
<person name="Tian L."/>
<person name="Kaehkoenen M."/>
<person name="Schwartzentruber J."/>
<person name="Kircher M."/>
<person name="Majewski J."/>
<person name="Dyment D.A."/>
<person name="Innes A.M."/>
<person name="Boycott K.M."/>
<person name="Moreau L.A."/>
<person name="Moilanen J.S."/>
<person name="Greenberg R.A."/>
</authorList>
<dbReference type="PubMed" id="25472942"/>
<dbReference type="DOI" id="10.1158/2159-8290.CD-14-1156"/>
</citation>
<scope>VARIANT FANCS TRP-1699</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="104">
<citation type="journal article" date="2017" name="Breast" volume="33" first="109" last="116">
<title>Suggestion of BRCA1 c.5339T&gt;C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea.</title>
<authorList>
<person name="Ryu J.M."/>
<person name="Kang G."/>
<person name="Nam S.J."/>
<person name="Kim S.W."/>
<person name="Yu J."/>
<person name="Lee S.K."/>
<person name="Bae S.Y."/>
<person name="Park S."/>
<person name="Paik H.J."/>
<person name="Kim J.W."/>
<person name="Park S.S."/>
<person name="Lee J.E."/>
<person name="Kim S.W."/>
</authorList>
<dbReference type="PubMed" id="28364669"/>
<dbReference type="DOI" id="10.1016/j.breast.2017.03.006"/>
</citation>
<scope>VARIANT BC PRO-1780</scope>
<scope>VARIANT BROVCA1 PRO-1780</scope>
<scope>VARIANT OC PRO-1780</scope>
</reference>
<reference key="105">
<citation type="journal article" date="2018" name="Eur. J. Med. Genet." volume="61" first="130" last="133">
<title>Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.</title>
<authorList>
<person name="Freire B.L."/>
<person name="Homma T.K."/>
<person name="Funari M.F.A."/>
<person name="Lerario A.M."/>
<person name="Leal A.M."/>
<person name="Velloso E.D.R.P."/>
<person name="Malaquias A.C."/>
<person name="Jorge A.A.L."/>
</authorList>
<dbReference type="PubMed" id="29133208"/>
<dbReference type="DOI" id="10.1016/j.ejmg.2017.11.003"/>
</citation>
<scope>VARIANT FANCS 903-CYS--TYR-1863 DEL</scope>
</reference>
<comment type="function">
<text evidence="23 24 32 41 42 47 48 56 58 60 64 69 71 73 74 75">E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator (PubMed:20160719).</text>
</comment>
<comment type="catalytic activity">
<reaction evidence="23 41 42 58 64 74">
<text>S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.</text>
<dbReference type="EC" id="2.3.2.27"/>
</reaction>
</comment>
<comment type="activity regulation">
<text evidence="64">The E3 ubiquitin-protein ligase activity is inhibited by phosphorylation by AURKA. Activity is increased by phosphatase treatment.</text>
</comment>
<comment type="pathway">
<text>Protein modification; protein ubiquitination.</text>
</comment>
<comment type="subunit">
<text evidence="24 25 27 28 29 30 31 32 33 36 37 42 44 47 48 50 51 53 55 56 57 58 60 61 62 66 68 69 70 71 72 73 74 78 79 80 82 84 85 86 100 102 104">Heterodimer with BARD1 (PubMed:11573085, PubMed:12890688, PubMed:14976165). Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the MRE11-RAD50-NBN protein (MRN) complex (PubMed:10783165). This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains (PubMed:10783165). Component of the BRCA1-A complex, at least composed of BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36, BABAM2 and BABAM1/NBA1 (PubMed:19261746, PubMed:19261748, PubMed:19261749, PubMed:20351172). Interacts (via the BRCT domains) with ABRAXAS1 (phosphorylated form); this is important for recruitment to sites of DNA damage (PubMed:17525340, PubMed:17643121, PubMed:17643122, PubMed:24316840, PubMed:26778126, PubMed:23269703). Can form a heterotetramer with two molecules of ABRAXAS1 (phosphorylated form) (PubMed:26778126). Component of the BRCA1-RBBP8 complex (PubMed:16101277). Interacts (via the BRCT domains) with RBBP8 ('Ser-327' phosphorylated form); the interaction ubiquitinates RBBP8, regulates CHEK1 activation, and involves RBBP8 in BRCA1-dependent G2/M checkpoint control on DNA damage (PubMed:16818604, PubMed:9811458). Associates with RNA polymerase II holoenzyme (PubMed:9662397). Interacts with SMC1A, NELFB, DCLRE1C, CLSPN (PubMed:11877377, PubMed:15096610, PubMed:15456891, PubMed:11739404). Interacts with CHEK1, CHEK2, BAP1, BRCC3, AURKA, UBXN1 and PCLAF (PubMed:10724175, PubMed:11836499, PubMed:14636569, PubMed:14990569, PubMed:20351172, PubMed:21673012). Interacts (via BRCT domains) with BRIP1 (phosphorylated form) (PubMed:11301010, PubMed:15133502, PubMed:21473589). Interacts with FANCD2 (ubiquitinated form) (PubMed:11239454). Interacts with H2AFX (phosphorylated on 'Ser-140') (PubMed:12419185). Interacts (via the BRCT domains) with ACACA (phosphorylated form); the interaction prevents dephosphorylation of ACACA (PubMed:12360400, PubMed:16326698, PubMed:16698035, PubMed:18452305). Part of a BRCA complex containing BRCA1, BRCA2 and PALB2 (PubMed:19369211). Interacts directly with PALB2; the interaction is essential for its function in HRR (PubMed:19369211, PubMed:28319063). Interacts directly with BRCA2; the interaction occurs only in the presence of PALB2 which serves as the bridging protein (PubMed:19369211). Interacts (via the BRCT domains) with LMO4; the interaction represses the transcriptional activity of BRCA1 (PubMed:11751867). Interacts (via the BRCT domains) with CCAR2 (via N-terminus); the interaction represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Interacts with EXD2 (PubMed:26807646). Interacts (via C-terminus) with DHX9; this interaction is direct and links BRCA1 to the RNA polymerase II holoenzyme (PubMed:9662397).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-349905"/>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-1263451">
<id>Q6UWZ7</id>
<label>ABRAXAS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>15</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-717681">
<id>Q13085</id>
<label>ACACA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-1791447">
<id>Q92560</id>
<label>BAP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-473181">
<id>Q99728</id>
<label>BARD1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>15</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-77694">
<id>P10415</id>
<label>BCL2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-349900">
<id>Q7Z569</id>
<label>BRAP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-10826195">
<id>Q6PJG6</id>
<label>BRAT1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-3509650">
<id>Q9BX63</id>
<label>BRIP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>19</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-375001">
<id>P24385</id>
<label>CCND1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-519526">
<id>P24864</id>
<label>CCNE1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-974488">
<id>O14757</id>
<label>CHEK1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-78473">
<id>P03372</id>
<label>ESR1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>12</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-78505">
<id>Q92731</id>
<label>ESR2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-904311">
<id>Q61188</id>
<label>Ezh2</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-701903">
<id>Q14192</id>
<label>FHL2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-359622">
<id>P78347</id>
<label>GTF2I</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-494830">
<id>P16104</id>
<label>H2AFX</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-2556203">
<id>O75330</id>
<label>HMMR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-352528">
<id>P10809</id>
<label>HSPD1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-2867186">
<id>Q16666</id>
<label>IFI16</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-349938">
<id>P52292</id>
<label>KPNA2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-495644">
<id>Q14676</id>
<label>MDC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-347721">
<id>Q8WX92</id>
<label>NELFB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-1222653">
<id>Q86YC2</id>
<label>PALB2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>27</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-357253">
<id>P62136</id>
<label>PPP1CA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-352350">
<id>P62140</id>
<label>PPP1CB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-356283">
<id>P36873</id>
<label>PPP1CC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-745715">
<id>Q99708</id>
<label>RBBP8</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>11</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-80140">
<id>P63165</id>
<label>SUMO1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-473220">
<id>P61956</id>
<label>SUMO2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-539628">
<id>P11388</id>
<label>TOP2A</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-396540">
<id>Q12888</id>
<label>TP53BP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-725300">
<id>Q96RL1</id>
<label>UIMC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>10</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-9640371">
<id>Q96RL1-1</id>
<label>UIMC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-1263058">
<id>Q6NZY4</id>
<label>ZCCHC8</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-349905"/>
<interactant intactId="EBI-396421">
<id>Q9GZX5</id>
<label>ZNF350</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="51 60 73 77 84 100">Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="80 83 84">Chromosome</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="73">Cytoplasm</location>
</subcellularLocation>
<text evidence="73 84">Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by ABRAXAS1 and the BRCA1-A complex (PubMed:26778126). Translocated to the cytoplasm during UV-induced apoptosis (PubMed:20160719).</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 5</molecule>
<subcellularLocation>
<location evidence="97">Cytoplasm</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<event type="alternative initiation"/>
<isoform>
<id>P38398-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P38398-2</id>
<name>2</name>
<sequence type="described" ref="VSP_047891"/>
<text>May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.</text>
</isoform>
<isoform>
<id>P38398-3</id>
<name>3</name>
<name>Delta11b</name>
<sequence type="described" ref="VSP_035399 VSP_043797"/>
</isoform>
<isoform>
<id>P38398-4</id>
<name>4</name>
<name>DeltaBRCA1(17aa)</name>
<sequence type="described" ref="VSP_035396"/>
<text>Produced by alternative initiation at Met-18 of isoform 1.</text>
</isoform>
<isoform>
<id>P38398-5</id>
<name>5</name>
<name>Delta11</name>
<name>Delta772-3095</name>
<sequence type="described" ref="VSP_035398"/>
</isoform>
<isoform>
<id>P38398-6</id>
<name>6</name>
<sequence type="described" ref="VSP_035399 VSP_043797 VSP_043798"/>
<text>No experimental confirmation available.</text>
</isoform>
<isoform>
<id>P38398-7</id>
<name>7</name>
<sequence type="described" ref="VSP_055404"/>
<text evidence="110">No experimental confirmation available. Ref.8 (AAI15038) sequence is in conflict in position: 1461:N-&gt;D.</text>
</isoform>
<isoform>
<id>P38398-8</id>
<name>8</name>
<sequence type="described" ref="VSP_057569"/>
<text evidence="110">No experimental confirmation available. The N-terminus is confirmed by several cDNAs.</text>
</isoform>
</comment>
<comment type="tissue specificity">
<text>Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.</text>
</comment>
<comment type="domain">
<text evidence="72">The BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of ABRAXAS1, recruits BRCA1 at DNA damage sites.</text>
</comment>
<comment type="domain">
<text evidence="72">The RING-type zinc finger domain interacts with BAP1.</text>
</comment>
<comment type="PTM">
<text evidence="24 26 34 48 64 75 77">Phosphorylation at Ser-308 by AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. Phosphorylation at Ser-988 by CHEK2 regulates mitotic spindle assembly.</text>
</comment>
<comment type="PTM">
<text evidence="42 74">Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.</text>
</comment>
<comment type="polymorphism">
<text>There is evidence that the presence of the rare form of Gln-356-Arg and Leu-871-Pro polymorphisms may be associated with an increased risk for developing ovarian cancer.</text>
</comment>
<comment type="disease" evidence="21 26 28 38 40 43 45 51 65 78 81 87 89 90 91 92 93 94 95 99 101 103">
<disease id="DI-02602">
<name>Breast cancer</name>
<acronym>BC</acronym>
<description>A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.</description>
<dbReference type="MIM" id="114480"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry. Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.</text>
</comment>
<comment type="disease" evidence="43 45 87 96">
<disease id="DI-01559">
<name>Breast-ovarian cancer, familial, 1</name>
<acronym>BROVCA1</acronym>
<description>A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.</description>
<dbReference type="MIM" id="604370"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.</text>
</comment>
<comment type="disease" evidence="20 22 46 87">
<disease id="DI-01655">
<name>Ovarian cancer</name>
<acronym>OC</acronym>
<description>The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.</description>
<dbReference type="MIM" id="167000"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="67">
<disease id="DI-03281">
<name>Pancreatic cancer 4</name>
<acronym>PNCA4</acronym>
<description>A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.</description>
<dbReference type="MIM" id="614320"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="80 83 88">
<disease id="DI-05209">
<name>Fanconi anemia, complementation group S</name>
<acronym>FANCS</acronym>
<description>A form of Fanconi anemia, a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.</description>
<dbReference type="MIM" id="617883"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="sequence caution" evidence="110">
<conflict type="erroneous translation">
<sequence resource="EMBL-CDS" id="AAB61673" version="1"/>
</conflict>
<text>Wrong choice of CDS.</text>
</comment>
<comment type="sequence caution" evidence="110">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAI15038" version="1"/>
</conflict>
<text>Translation N-terminally extended.</text>
</comment>
<comment type="sequence caution" evidence="110">
<conflict type="erroneous termination">
<sequence resource="EMBL-CDS" id="AAI15038" version="1"/>
</conflict>
<location>
<position position="526"/>
</location>
<text>Translated as Gln.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/BRCA1ID163ch17q21.html"/>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/brca1/"/>
</comment>
<comment type="online information" name="SHMPD">
<link uri="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&amp;genename=BRCA1"/>
<text>The Singapore human mutation and polymorphism database</text>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/BRCA1"/>
<text>BRCA1 entry</text>
</comment>
<dbReference type="EC" id="2.3.2.27" evidence="23 41 42 58 64 74"/>
<dbReference type="EMBL" id="U14680">
<property type="protein sequence ID" value="AAA73985.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L78833">
<property type="protein sequence ID" value="AAC37594.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="U64805">
<property type="protein sequence ID" value="AAC00049.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF005068">
<property type="protein sequence ID" value="AAB61673.1"/>
<property type="status" value="ALT_SEQ"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190450">
<property type="protein sequence ID" value="ABA29208.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190451">
<property type="protein sequence ID" value="ABA29211.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190452">
<property type="protein sequence ID" value="ABA29214.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190453">
<property type="protein sequence ID" value="ABA29217.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190454">
<property type="protein sequence ID" value="ABA29220.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190455">
<property type="protein sequence ID" value="ABA29223.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ190456">
<property type="protein sequence ID" value="ABA29226.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AY273801">
<property type="protein sequence ID" value="AAP12647.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC060780">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC135721">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC072418">
<property type="protein sequence ID" value="AAH72418.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC115037">
<property type="protein sequence ID" value="AAI15038.1"/>
<property type="status" value="ALT_SEQ"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11453.1">
<molecule id="P38398-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11454.2">
<molecule id="P38398-3"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11455.2">
<molecule id="P38398-6"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11456.2">
<molecule id="P38398-7"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11459.2">
<molecule id="P38398-8"/>
</dbReference>
<dbReference type="PIR" id="A58881">
<property type="entry name" value="A58881"/>
</dbReference>
<dbReference type="RefSeq" id="NP_009225.1">
<molecule id="P38398-1"/>
<property type="nucleotide sequence ID" value="NM_007294.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_009228.2">
<molecule id="P38398-8"/>
<property type="nucleotide sequence ID" value="NM_007297.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_009229.2">
<molecule id="P38398-3"/>
<property type="nucleotide sequence ID" value="NM_007298.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_009230.2">
<molecule id="P38398-6"/>
<property type="nucleotide sequence ID" value="NM_007299.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_009231.2">
<molecule id="P38398-7"/>
<property type="nucleotide sequence ID" value="NM_007300.3"/>
</dbReference>
<dbReference type="PDB" id="1JM7">
<property type="method" value="NMR"/>
<property type="chains" value="A=1-110"/>
</dbReference>
<dbReference type="PDB" id="1JNX">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="X=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1N5O">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="X=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1OQA">
<property type="method" value="NMR"/>
<property type="chains" value="A=1755-1863"/>
</dbReference>
<dbReference type="PDB" id="1T15">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1T29">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1T2U">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1T2V">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.30"/>
<property type="chains" value="A/B/C/D/E=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="1Y98">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="2ING">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.60"/>
<property type="chains" value="X=1649-1859"/>
</dbReference>
<dbReference type="PDB" id="3COJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.21"/>
<property type="chains" value="A/B/C/D/E/F/G/X=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3K0H">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3K0K">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3K15">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3K16">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3PXA">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.55"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3PXB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3PXC">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="X=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3PXD">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="3PXE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.85"/>
<property type="chains" value="A/B/C/D=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4IFI">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4IGK">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.75"/>
<property type="chains" value="A/B=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4JLU">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="A=1649-1859"/>
</dbReference>
<dbReference type="PDB" id="4OFB">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.05"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4U4A">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.51"/>
<property type="chains" value="A/B/C=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4Y18">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.50"/>
<property type="chains" value="A/B/C/D/E/F/G/H=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="4Y2G">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=1646-1859"/>
</dbReference>
<dbReference type="PDB" id="6G2I">
<property type="method" value="EM"/>
<property type="resolution" value="5.90"/>
<property type="chains" value="H/K/M/O/S/U/W/Y=1646-1859"/>
</dbReference>
<dbReference type="PDBsum" id="1JM7"/>
<dbReference type="PDBsum" id="1JNX"/>
<dbReference type="PDBsum" id="1N5O"/>
<dbReference type="PDBsum" id="1OQA"/>
<dbReference type="PDBsum" id="1T15"/>
<dbReference type="PDBsum" id="1T29"/>
<dbReference type="PDBsum" id="1T2U"/>
<dbReference type="PDBsum" id="1T2V"/>
<dbReference type="PDBsum" id="1Y98"/>
<dbReference type="PDBsum" id="2ING"/>
<dbReference type="PDBsum" id="3COJ"/>
<dbReference type="PDBsum" id="3K0H"/>
<dbReference type="PDBsum" id="3K0K"/>
<dbReference type="PDBsum" id="3K15"/>
<dbReference type="PDBsum" id="3K16"/>
<dbReference type="PDBsum" id="3PXA"/>
<dbReference type="PDBsum" id="3PXB"/>
<dbReference type="PDBsum" id="3PXC"/>
<dbReference type="PDBsum" id="3PXD"/>
<dbReference type="PDBsum" id="3PXE"/>
<dbReference type="PDBsum" id="4IFI"/>
<dbReference type="PDBsum" id="4IGK"/>
<dbReference type="PDBsum" id="4JLU"/>
<dbReference type="PDBsum" id="4OFB"/>
<dbReference type="PDBsum" id="4U4A"/>
<dbReference type="PDBsum" id="4Y18"/>
<dbReference type="PDBsum" id="4Y2G"/>
<dbReference type="PDBsum" id="6G2I"/>
<dbReference type="SMR" id="P38398"/>
<dbReference type="BioGrid" id="107140">
<property type="interactions" value="1010"/>
</dbReference>
<dbReference type="ComplexPortal" id="CPX-955">
<property type="entry name" value="BRCC ubiquitin ligase complex"/>
</dbReference>
<dbReference type="CORUM" id="P38398"/>
<dbReference type="DIP" id="DIP-5971N"/>
<dbReference type="IntAct" id="P38398">
<property type="interactions" value="216"/>
</dbReference>
<dbReference type="MINT" id="P38398"/>
<dbReference type="STRING" id="9606.ENSP00000418960"/>
<dbReference type="BindingDB" id="P38398"/>
<dbReference type="ChEMBL" id="CHEMBL5990"/>
<dbReference type="GlyConnect" id="2024"/>
<dbReference type="iPTMnet" id="P38398"/>
<dbReference type="PhosphoSitePlus" id="P38398"/>
<dbReference type="BioMuta" id="BRCA1"/>
<dbReference type="DMDM" id="728984"/>
<dbReference type="CPTAC" id="CPTAC-2610"/>
<dbReference type="CPTAC" id="CPTAC-2611"/>
<dbReference type="CPTAC" id="CPTAC-3218"/>
<dbReference type="CPTAC" id="CPTAC-3219"/>
<dbReference type="CPTAC" id="CPTAC-916"/>
<dbReference type="EPD" id="P38398"/>
<dbReference type="jPOST" id="P38398"/>
<dbReference type="PaxDb" id="P38398"/>
<dbReference type="PeptideAtlas" id="P38398"/>
<dbReference type="PRIDE" id="P38398"/>
<dbReference type="ProteomicsDB" id="20208"/>
<dbReference type="ProteomicsDB" id="55287">
<molecule id="P38398-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="55288">
<molecule id="P38398-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="55289">
<molecule id="P38398-3"/>
</dbReference>
<dbReference type="ProteomicsDB" id="55290">
<molecule id="P38398-4"/>
</dbReference>
<dbReference type="ProteomicsDB" id="55291">
<molecule id="P38398-5"/>
</dbReference>
<dbReference type="ProteomicsDB" id="55292">
<molecule id="P38398-6"/>
</dbReference>
<dbReference type="DNASU" id="672"/>
<dbReference type="Ensembl" id="ENST00000352993">
<molecule id="P38398-5"/>
<property type="protein sequence ID" value="ENSP00000312236"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000357654">
<molecule id="P38398-1"/>
<property type="protein sequence ID" value="ENSP00000350283"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000461221">
<molecule id="P38398-2"/>
<property type="protein sequence ID" value="ENSP00000418548"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000461798">
<molecule id="P38398-2"/>
<property type="protein sequence ID" value="ENSP00000417988"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000468300">
<molecule id="P38398-6"/>
<property type="protein sequence ID" value="ENSP00000417148"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000471181">
<molecule id="P38398-7"/>
<property type="protein sequence ID" value="ENSP00000418960"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000491747">
<molecule id="P38398-3"/>
<property type="protein sequence ID" value="ENSP00000420705"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000493795">
<molecule id="P38398-8"/>
<property type="protein sequence ID" value="ENSP00000418775"/>
<property type="gene ID" value="ENSG00000012048"/>
</dbReference>
<dbReference type="GeneID" id="672"/>
<dbReference type="KEGG" id="hsa:672"/>
<dbReference type="UCSC" id="uc002icq.4">
<molecule id="P38398-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="UCSC" id="uc010cyx.4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="672"/>
<dbReference type="DisGeNET" id="672"/>
<dbReference type="GeneCards" id="BRCA1"/>
<dbReference type="GeneReviews" id="BRCA1"/>
<dbReference type="HGNC" id="HGNC:1100">
<property type="gene designation" value="BRCA1"/>
</dbReference>
<dbReference type="HPA" id="CAB001946"/>
<dbReference type="HPA" id="HPA034966"/>
<dbReference type="HPA" id="HPA057371"/>
<dbReference type="MalaCards" id="BRCA1"/>
<dbReference type="MIM" id="113705">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="114480">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="167000">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="604370">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="614320">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="617883">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P38398"/>
<dbReference type="OpenTargets" id="ENSG00000012048"/>
<dbReference type="Orphanet" id="1333">
<property type="disease" value="Familial pancreatic carcinoma"/>
</dbReference>
<dbReference type="Orphanet" id="1331">
<property type="disease" value="Familial prostate cancer"/>
</dbReference>
<dbReference type="Orphanet" id="84">
<property type="disease" value="Fanconi anemia"/>
</dbReference>
<dbReference type="Orphanet" id="145">
<property type="disease" value="Hereditary breast and ovarian cancer syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="227535">
<property type="disease" value="Hereditary breast cancer"/>
</dbReference>
<dbReference type="Orphanet" id="213524">
<property type="disease" value="Hereditary site-specific ovarian cancer syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="168829">
<property type="disease" value="Primary peritoneal carcinoma"/>
</dbReference>
<dbReference type="PharmGKB" id="PA25411"/>
<dbReference type="eggNOG" id="ENOG410ITQ4">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="ENOG4112BIH">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00440000034289"/>
<dbReference type="HOGENOM" id="HOG000230969"/>
<dbReference type="InParanoid" id="P38398"/>
<dbReference type="KO" id="K10605"/>
<dbReference type="OMA" id="RWAESKE"/>
<dbReference type="OrthoDB" id="496760at2759"/>
<dbReference type="PhylomeDB" id="P38398"/>
<dbReference type="BRENDA" id="6.3.2.19">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1221632">
<property type="pathway name" value="Meiotic synapsis"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3108214">
<property type="pathway name" value="SUMOylation of DNA damage response and repair proteins"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5685938">
<property type="pathway name" value="HDR through Single Strand Annealing (SSA)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5685942">
<property type="pathway name" value="HDR through Homologous Recombination (HRR)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5689901">
<property type="pathway name" value="Metalloprotease DUBs"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693554">
<property type="pathway name" value="Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693565">
<property type="pathway name" value="Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693568">
<property type="pathway name" value="Resolution of D-loop Structures through Holliday Junction Intermediates"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693571">
<property type="pathway name" value="Nonhomologous End-Joining (NHEJ)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693579">
<property type="pathway name" value="Homologous DNA Pairing and Strand Exchange"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693607">
<property type="pathway name" value="Processing of DNA double-strand break ends"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5693616">
<property type="pathway name" value="Presynaptic phase of homologous DNA pairing and strand exchange"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6796648">
<property type="pathway name" value="TP53 Regulates Transcription of DNA Repair Genes"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6804756">
<property type="pathway name" value="Regulation of TP53 Activity through Phosphorylation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-69473">
<property type="pathway name" value="G2/M DNA damage checkpoint"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8953750">
<property type="pathway name" value="Transcriptional Regulation by E2F6"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-912446">
<property type="pathway name" value="Meiotic recombination"/>
</dbReference>
<dbReference type="SignaLink" id="P38398"/>
<dbReference type="SIGNOR" id="P38398"/>
<dbReference type="UniPathway" id="UPA00143"/>
<dbReference type="ChiTaRS" id="BRCA1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P38398"/>
<dbReference type="GeneWiki" id="BRCA1"/>
<dbReference type="GenomeRNAi" id="672"/>
<dbReference type="PMAP-CutDB" id="P38398"/>
<dbReference type="PRO" id="PR:P38398"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 17"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000012048">
<property type="expression patterns" value="Expressed in 179 organ(s), highest expression level in lung"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P38398">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P38398">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0070531">
<property type="term" value="C:BRCA1-A complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031436">
<property type="term" value="C:BRCA1-BARD1 complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005694">
<property type="term" value="C:chromosome"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008274">
<property type="term" value="C:gamma-tubulin ring complex"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000800">
<property type="term" value="C:lateral element"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032991">
<property type="term" value="C:protein-containing complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1990904">
<property type="term" value="C:ribonucleoprotein complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0000151">
<property type="term" value="C:ubiquitin ligase complex"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050681">
<property type="term" value="F:androgen receptor binding"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003684">
<property type="term" value="F:damaged DNA binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0003677">
<property type="term" value="F:DNA binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0019899">
<property type="term" value="F:enzyme binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="IntAct"/>
</dbReference>
<dbReference type="GO" id="GO:0003723">
<property type="term" value="F:RNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0070063">
<property type="term" value="F:RNA polymerase binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003713">
<property type="term" value="F:transcription coactivator activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0044212">
<property type="term" value="F:transcription regulatory region DNA binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0015631">
<property type="term" value="F:tubulin binding"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031625">
<property type="term" value="F:ubiquitin protein ligase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004842">
<property type="term" value="F:ubiquitin-protein transferase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008270">
<property type="term" value="F:zinc ion binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0030521">
<property type="term" value="P:androgen receptor signaling pathway"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006915">
<property type="term" value="P:apoptotic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006974">
<property type="term" value="P:cellular response to DNA damage stimulus"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0071681">
<property type="term" value="P:cellular response to indole-3-methanol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071356">
<property type="term" value="P:cellular response to tumor necrosis factor"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007098">
<property type="term" value="P:centrosome cycle"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043009">
<property type="term" value="P:chordate embryonic development"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0007059">
<property type="term" value="P:chromosome segregation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006978">
<property type="term" value="P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000729">
<property type="term" value="P:DNA double-strand break processing"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006260">
<property type="term" value="P:DNA replication"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0009048">
<property type="term" value="P:dosage compensation by inactivation of X chromosome"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0006302">
<property type="term" value="P:double-strand break repair"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="CACAO"/>
</dbReference>
<dbReference type="GO" id="GO:0000724">
<property type="term" value="P:double-strand break repair via homologous recombination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0006303">
<property type="term" value="P:double-strand break repair via nonhomologous end joining"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006633">
<property type="term" value="P:fatty acid biosynthetic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0008630">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to DNA damage"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0044818">
<property type="term" value="P:mitotic G2/M transition checkpoint"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0046600">
<property type="term" value="P:negative regulation of centriole replication"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902042">
<property type="term" value="P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045717">
<property type="term" value="P:negative regulation of fatty acid biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070317">
<property type="term" value="P:negative regulation of G0 to G1 transition"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0035067">
<property type="term" value="P:negative regulation of histone acetylation"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0051572">
<property type="term" value="P:negative regulation of histone H3-K4 methylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051573">
<property type="term" value="P:negative regulation of histone H3-K9 methylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0033147">
<property type="term" value="P:negative regulation of intracellular estrogen receptor signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="CACAO"/>
</dbReference>
<dbReference type="GO" id="GO:2000378">
<property type="term" value="P:negative regulation of reactive oxygen species metabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045892">
<property type="term" value="P:negative regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045766">
<property type="term" value="P:positive regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071158">
<property type="term" value="P:positive regulation of cell cycle arrest"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045739">
<property type="term" value="P:positive regulation of DNA repair"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010628">
<property type="term" value="P:positive regulation of gene expression"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035066">
<property type="term" value="P:positive regulation of histone acetylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051571">
<property type="term" value="P:positive regulation of histone H3-K4 methylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:2000617">
<property type="term" value="P:positive regulation of histone H3-K9 acetylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051574">
<property type="term" value="P:positive regulation of histone H3-K9 methylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2000620">
<property type="term" value="P:positive regulation of histone H4-K16 acetylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0070512">
<property type="term" value="P:positive regulation of histone H4-K20 methylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0031398">
<property type="term" value="P:positive regulation of protein ubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045944">
<property type="term" value="P:positive regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010575">
<property type="term" value="P:positive regulation of vascular endothelial growth factor production"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006301">
<property type="term" value="P:postreplication repair"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0051865">
<property type="term" value="P:protein autoubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016579">
<property type="term" value="P:protein deubiquitination"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0085020">
<property type="term" value="P:protein K6-linked ubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016567">
<property type="term" value="P:protein ubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HGNC"/>
</dbReference>
<dbReference type="GO" id="GO:0042981">
<property type="term" value="P:regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042127">
<property type="term" value="P:regulation of cell population proliferation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0044030">
<property type="term" value="P:regulation of DNA methylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006349">
<property type="term" value="P:regulation of gene expression by genetic imprinting"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1901796">
<property type="term" value="P:regulation of signal transduction by p53 class mediator"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006357">
<property type="term" value="P:regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006359">
<property type="term" value="P:regulation of transcription by RNA polymerase III"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043627">
<property type="term" value="P:response to estrogen"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010212">
<property type="term" value="P:response to ionizing radiation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0072425">
<property type="term" value="P:signal transduction involved in G2 DNA damage checkpoint"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="DisProt" id="DP00238"/>
<dbReference type="Gene3D" id="3.30.40.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.40.50.10190">
<property type="match status" value="2"/>
</dbReference>
<dbReference type="InterPro" id="IPR011364">
<property type="entry name" value="BRCA1"/>
</dbReference>
<dbReference type="InterPro" id="IPR031099">
<property type="entry name" value="BRCA1-associated"/>
</dbReference>
<dbReference type="InterPro" id="IPR025994">
<property type="entry name" value="BRCA1_serine_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001357">
<property type="entry name" value="BRCT_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR036420">
<property type="entry name" value="BRCT_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR018957">
<property type="entry name" value="Znf_C3HC4_RING-type"/>
</dbReference>
<dbReference type="InterPro" id="IPR001841">
<property type="entry name" value="Znf_RING"/>
</dbReference>
<dbReference type="InterPro" id="IPR013083">
<property type="entry name" value="Znf_RING/FYVE/PHD"/>
</dbReference>
<dbReference type="InterPro" id="IPR017907">
<property type="entry name" value="Znf_RING_CS"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR13763">
<property type="entry name" value="PTHR13763"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR13763:SF0">
<property type="entry name" value="PTHR13763:SF0"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00533">
<property type="entry name" value="BRCT"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Pfam" id="PF12820">
<property type="entry name" value="BRCT_assoc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00097">
<property type="entry name" value="zf-C3HC4"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF001734">
<property type="entry name" value="BRCA1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00493">
<property type="entry name" value="BRSTCANCERI"/>
</dbReference>
<dbReference type="SMART" id="SM00292">
<property type="entry name" value="BRCT"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="SMART" id="SM00184">
<property type="entry name" value="RING"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52113">
<property type="entry name" value="SSF52113"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS50172">
<property type="entry name" value="BRCT"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00518">
<property type="entry name" value="ZF_RING_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50089">
<property type="entry name" value="ZF_RING_2"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0007">Acetylation</keyword>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0024">Alternative initiation</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0131">Cell cycle</keyword>
<keyword id="KW-0158">Chromosome</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0227">DNA damage</keyword>
<keyword id="KW-0233">DNA recombination</keyword>
<keyword id="KW-0234">DNA repair</keyword>
<keyword id="KW-0238">DNA-binding</keyword>
<keyword id="KW-0923">Fanconi anemia</keyword>
<keyword id="KW-0275">Fatty acid biosynthesis</keyword>
<keyword id="KW-0276">Fatty acid metabolism</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0444">Lipid biosynthesis</keyword>
<keyword id="KW-0443">Lipid metabolism</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0043">Tumor suppressor</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0833">Ubl conjugation pathway</keyword>
<keyword id="KW-0862">Zinc</keyword>
<keyword id="KW-0863">Zinc-finger</keyword>
<feature type="chain" description="Breast cancer type 1 susceptibility protein" id="PRO_0000055830">
<location>
<begin position="1"/>
<end position="1863"/>
</location>
</feature>
<feature type="domain" description="BRCT 1" evidence="18">
<location>
<begin position="1642"/>
<end position="1736"/>
</location>
</feature>
<feature type="domain" description="BRCT 2" evidence="18">
<location>
<begin position="1756"/>
<end position="1855"/>
</location>
</feature>
<feature type="zinc finger region" description="RING-type" evidence="19">
<location>
<begin position="24"/>
<end position="65"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with PALB2" evidence="71">
<location>
<begin position="1397"/>
<end position="1424"/>
</location>
</feature>
<feature type="compositionally biased region" description="Poly-Lys">
<location>
<begin position="651"/>
<end position="654"/>
</location>
</feature>
<feature type="modified residue" description="N-acetylmethionine" evidence="12">
<location>
<position position="1"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10 11 13">
<location>
<position position="114"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by AURKA" evidence="48">
<location>
<position position="308"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8 9">
<location>
<position position="395"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8 9">
<location>
<position position="398"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="423"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="434"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="551"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10 13">
<location>
<position position="694"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="708"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="17">
<location>
<position position="725"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8">
<location>
<position position="753"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="17">
<location>
<position position="840"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by CHEK2" evidence="24 75">
<location>
<position position="988"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="1009"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATR; in vitro" evidence="26">
<location>
<position position="1143"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="1189"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="1191"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8">
<location>
<position position="1211"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8">
<location>
<position position="1217"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8 11">
<location>
<position position="1218"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATR; in vitro" evidence="26">
<location>
<position position="1280"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="1328"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="7 10 11">
<location>
<position position="1336"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10 11">
<location>
<position position="1342"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATM and ATR" evidence="26">
<location>
<position position="1387"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by ATR; in vitro" evidence="26">
<location>
<position position="1394"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATM and ATR" evidence="26">
<location>
<position position="1423"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATR; in vitro" evidence="26">
<location>
<position position="1457"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by ATM" evidence="77">
<location>
<position position="1524"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="13">
<location>
<position position="1542"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="109"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="301"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14 15 16">
<location>
<position position="339"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="15 16">
<location>
<position position="443"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14 16">
<location>
<position position="459"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="519"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14 15 16">
<location>
<position position="583"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14">
<location>
<position position="654"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14">
<location>
<position position="734"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="14">
<location>
<position position="739"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="918"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="987"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="16">
<location>
<position position="1079"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 8." id="VSP_057569">
<location>
<begin position="1"/>
<end position="47"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_035396" evidence="110">
<location>
<begin position="1"/>
<end position="17"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_047891" evidence="109">
<location>
<begin position="64"/>
<end position="1863"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_035398" evidence="110">
<location>
<begin position="224"/>
<end position="1365"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3 and isoform 6." id="VSP_035399" evidence="107 108">
<location>
<begin position="264"/>
<end position="1366"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3 and isoform 6." id="VSP_043797" evidence="107 108">
<location>
<position position="1453"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 7." id="VSP_055404" evidence="107">
<original>A</original>
<variation>DSHIHGQRNNSMFSKRPREHIS</variation>
<location>
<position position="1453"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 6." id="VSP_043798" evidence="107">
<original>DQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY</original>
<variation>GCPPNCGCAARCLDRGQWLPCNWADV</variation>
<location>
<begin position="1778"/>
<end position="1863"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs786203152." id="VAR_070458" evidence="81">
<original>S</original>
<variation>F</variation>
<location>
<position position="4"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and BROVCA1." id="VAR_020679" evidence="45">
<original>E</original>
<variation>K</variation>
<location>
<position position="10"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast-ovarian cancer patients; unknown pathological significance; dbSNP:rs80357017." id="VAR_007754">
<original>V</original>
<variation>A</variation>
<location>
<position position="11"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356929." id="VAR_063899" evidence="63 81">
<original>M</original>
<variation>T</variation>
<location>
<position position="18"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast-ovarian cancer patients; unknown pathological significance; dbSNP:rs80357406." id="VAR_007755">
<original>I</original>
<variation>V</variation>
<location>
<position position="21"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs80357438." id="VAR_007756" evidence="101">
<original>L</original>
<variation>S</variation>
<location>
<position position="22"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and BROVCA1." id="VAR_020680" evidence="45">
<original>E</original>
<variation>K</variation>
<location>
<position position="23"/>
</location>
</feature>
<feature type="sequence variant" description="In a breast cancer sample; somatic mutation." id="VAR_035947" evidence="59">
<original>L</original>
<variation>F</variation>
<location>
<position position="30"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs769650474." id="VAR_070459" evidence="81">
<original>K</original>
<variation>Q</variation>
<location>
<position position="45"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and ovarian cancer; no interaction with BAP1; dbSNP:rs28897672." id="VAR_007757" evidence="43 46 81 91 93 100 103">
<original>C</original>
<variation>G</variation>
<location>
<position position="61"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; no interaction with BAP1; dbSNP:rs80357064." id="VAR_007758" evidence="81 90 99 100">
<original>C</original>
<variation>G</variation>
<location>
<position position="64"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55851803." id="VAR_007759">
<original>C</original>
<variation>Y</variation>
<location>
<position position="64"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357102." id="VAR_070460" evidence="81">
<original>D</original>
<variation>Y</variation>
<location>
<position position="67"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356913." id="VAR_020681" evidence="43">
<original>R</original>
<variation>K</variation>
<location>
<position position="71"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28897673." id="VAR_070461" evidence="81">
<original>Y</original>
<variation>C</variation>
<location>
<position position="105"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357413." id="VAR_070462" evidence="81">
<original>N</original>
<variation>K</variation>
<location>
<position position="132"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs55971303." id="VAR_070463" evidence="81">
<original>P</original>
<variation>H</variation>
<location>
<position position="142"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs748876625." id="VAR_070464" evidence="81">
<original>L</original>
<variation>F</variation>
<location>
<position position="147"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28897674." id="VAR_052077">
<original>S</original>
<variation>R</variation>
<location>
<position position="153"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070465" evidence="81">
<original>L</original>
<variation>P</variation>
<location>
<position position="165"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357325." id="VAR_070466" evidence="81">
<original>R</original>
<variation>W</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs55688530." id="VAR_070467" evidence="81">
<original>S</original>
<variation>Y</variation>
<location>
<position position="186"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357090." id="VAR_070468" evidence="81">
<original>V</original>
<variation>I</variation>
<location>
<position position="191"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance." id="VAR_008759">
<original>E</original>
<variation>K</variation>
<location>
<position position="227"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357001." id="VAR_070469" evidence="81">
<original>T</original>
<variation>M</variation>
<location>
<position position="231"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs80357396." id="VAR_007760" evidence="98 103">
<original>H</original>
<variation>R</variation>
<location>
<position position="239"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80356865." id="VAR_070470" evidence="81">
<original>D</original>
<variation>V</variation>
<location>
<position position="245"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897675." id="VAR_070471" evidence="81">
<original>L</original>
<variation>V</variation>
<location>
<position position="246"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357244." id="VAR_070472" evidence="81">
<original>V</original>
<variation>L</variation>
<location>
<position position="271"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs80357244." id="VAR_007761" evidence="94">
<original>V</original>
<variation>M</variation>
<location>
<position position="271"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs8176153." id="VAR_019944" evidence="106">
<original>G</original>
<variation>S</variation>
<location>
<position position="275"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357015." id="VAR_008760" evidence="21">
<original>P</original>
<variation>S</variation>
<location>
<position position="346"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs1799950." id="VAR_007762" evidence="91 105 106">
<original>Q</original>
<variation>R</variation>
<location>
<position position="356"/>
</location>
</feature>
<feature type="sequence variant" description="In BC." id="VAR_007763">
<location>
<position position="369"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56128296." id="VAR_007764">
<original>I</original>
<variation>M</variation>
<location>
<position position="379"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs56046357." id="VAR_007765" evidence="101">
<original>F</original>
<variation>L</variation>
<location>
<position position="461"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397508869." id="VAR_007766" evidence="101">
<original>Y</original>
<variation>D</variation>
<location>
<position position="465"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast-ovarian cancer patients; unknown pathological significance; dbSNP:rs80357224." id="VAR_007767">
<original>R</original>
<variation>I</variation>
<location>
<position position="507"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397508893." id="VAR_007768" evidence="101">
<original>G</original>
<variation>V</variation>
<location>
<position position="552"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_020682" evidence="39">
<original>N</original>
<variation>I</variation>
<location>
<position position="656"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357250." id="VAR_070473" evidence="81">
<original>L</original>
<variation>F</variation>
<location>
<position position="668"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs4986850." id="VAR_007769" evidence="49 106">
<original>D</original>
<variation>N</variation>
<location>
<position position="693"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897681." id="VAR_070474" evidence="81">
<original>D</original>
<variation>N</variation>
<location>
<position position="695"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs4986845." id="VAR_020110">
<original>N</original>
<variation>D</variation>
<location>
<position position="723"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs80357114." id="VAR_020683" evidence="40">
<original>D</original>
<variation>Y</variation>
<location>
<position position="749"/>
</location>
</feature>
<feature type="sequence variant" description="In a breast cancer sample; somatic mutation." id="VAR_035948" evidence="59">
<original>L</original>
<variation>F</variation>
<location>
<position position="758"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs80357467." id="VAR_007770" evidence="90 99">
<original>V</original>
<variation>A</variation>
<location>
<position position="772"/>
</location>
</feature>
<feature type="sequence variant" description="In a breast cancer sample; somatic mutation." id="VAR_035949" evidence="59">
<original>G</original>
<variation>C</variation>
<location>
<position position="778"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs876660005." id="VAR_070475" evidence="81">
<original>P</original>
<variation>L</variation>
<location>
<position position="798"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897682." id="VAR_070476" evidence="81">
<original>N</original>
<variation>Y</variation>
<location>
<position position="810"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs56082113." id="VAR_007771" evidence="99">
<original>K</original>
<variation>E</variation>
<location>
<position position="820"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897683." id="VAR_007772" evidence="81">
<original>T</original>
<variation>K</variation>
<location>
<position position="826"/>
</location>
</feature>
<feature type="sequence variant" description="In BROVCA1; unknown pathological significance; dbSNP:rs751656678." id="VAR_020684" evidence="43">
<original>H</original>
<variation>Y</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357337." id="VAR_070477" evidence="81">
<original>R</original>
<variation>Q</variation>
<location>
<position position="841"/>
</location>
</feature>
<feature type="sequence variant" description="In BROVCA1; unknown pathological significance; dbSNP:rs1800709." id="VAR_007773" evidence="96 103">
<original>R</original>
<variation>W</variation>
<location>
<position position="841"/>
</location>
</feature>
<feature type="sequence variant" description="In a patient with sporadic breast cancer; unknown pathological significance; dbSNP:rs80356892." id="VAR_020685" evidence="52 81">
<original>Y</original>
<variation>H</variation>
<location>
<position position="856"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs41286300." id="VAR_070478" evidence="81">
<original>R</original>
<variation>C</variation>
<location>
<position position="866"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance." id="VAR_020686" evidence="43">
<original>R</original>
<variation>Q</variation>
<location>
<position position="866"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs799917." id="VAR_007774" evidence="21 39 52 54 106">
<original>P</original>
<variation>L</variation>
<location>
<position position="871"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357480." id="VAR_020687" evidence="43">
<original>H</original>
<variation>Y</variation>
<location>
<position position="888"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397508994." id="VAR_007775" evidence="101">
<original>L</original>
<variation>S</variation>
<location>
<position position="892"/>
</location>
</feature>
<feature type="sequence variant" description="In FANCS." id="VAR_080693" evidence="88">
<location>
<begin position="903"/>
<end position="1863"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs4986847." id="VAR_021913">
<original>I</original>
<variation>L</variation>
<location>
<position position="925"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397509022." id="VAR_007776" evidence="101">
<original>G</original>
<variation>D</variation>
<location>
<position position="960"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs4986848." id="VAR_020111">
<original>F</original>
<variation>S</variation>
<location>
<position position="989"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs1800704." id="VAR_007777">
<original>M</original>
<variation>I</variation>
<location>
<position position="1008"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397509034." id="VAR_007778" evidence="101">
<original>T</original>
<variation>I</variation>
<location>
<position position="1025"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs16941." id="VAR_007779" evidence="21 52 54 91 106">
<original>E</original>
<variation>G</variation>
<location>
<position position="1038"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs4986852." id="VAR_007780" evidence="49 90 91 99 106">
<original>S</original>
<variation>N</variation>
<location>
<position position="1040"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs397509037." id="VAR_007781" evidence="101">
<original>V</original>
<variation>A</variation>
<location>
<position position="1047"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs80357184." id="VAR_020688" evidence="49 81">
<original>E</original>
<variation>A</variation>
<location>
<position position="1060"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs41293447." id="VAR_070479" evidence="81">
<original>S</original>
<variation>N</variation>
<location>
<position position="1101"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357228." id="VAR_020689" evidence="43">
<original>S</original>
<variation>I</variation>
<location>
<position position="1139"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs2227945." id="VAR_019945" evidence="81 106">
<original>S</original>
<variation>G</variation>
<location>
<position position="1140"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070480" evidence="81">
<original>S</original>
<variation>N</variation>
<location>
<position position="1140"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; dbSNP:rs80357272." id="VAR_007782" evidence="94">
<original>P</original>
<variation>S</variation>
<location>
<position position="1150"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs16942." id="VAR_007783" evidence="21 45 52 54 91 106">
<original>K</original>
<variation>R</variation>
<location>
<position position="1183"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and BROVCA1." id="VAR_020690" evidence="45">
<original>S</original>
<variation>I</variation>
<location>
<position position="1187"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and BROVCA1; dbSNP:rs56214134." id="VAR_020691" evidence="45">
<original>Q</original>
<variation>H</variation>
<location>
<position position="1200"/>
</location>
</feature>
<feature type="sequence variant" description="In BC." id="VAR_020692" evidence="45">
<original>R</original>
<variation>I</variation>
<location>
<position position="1204"/>
</location>
</feature>
<feature type="sequence variant" description="In BC." id="VAR_020693" evidence="45">
<original>K</original>
<variation>N</variation>
<location>
<position position="1207"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs1060502347." id="VAR_020694" evidence="43">
<original>E</original>
<variation>G</variation>
<location>
<position position="1210"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80356923." id="VAR_070481" evidence="81">
<original>E</original>
<variation>K</variation>
<location>
<position position="1214"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and BROVCA1." id="VAR_020695" evidence="45">
<original>S</original>
<variation>Y</variation>
<location>
<position position="1217"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast-ovarian cancer patients; unknown pathological significance; dbSNP:rs80356876." id="VAR_007784">
<original>E</original>
<variation>D</variation>
<location>
<position position="1219"/>
</location>
</feature>
<feature type="sequence variant" description="In BROVCA1." id="VAR_020696" evidence="45">
<original>F</original>
<variation>L</variation>
<location>
<position position="1226"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897687." id="VAR_052078" evidence="81">
<original>N</original>
<variation>K</variation>
<location>
<position position="1236"/>
</location>
</feature>
<feature type="sequence variant" description="In BROVCA1." id="VAR_020697" evidence="45">
<original>R</original>
<variation>G</variation>
<location>
<position position="1243"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28897686." id="VAR_052079" evidence="81">
<original>E</original>
<variation>K</variation>
<location>
<position position="1250"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs587782190." id="VAR_070482" evidence="81">
<original>L</original>
<variation>S</variation>
<location>
<position position="1267"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357217." id="VAR_070483" evidence="81">
<original>E</original>
<variation>V</variation>
<location>
<position position="1282"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs1450793674." id="VAR_020698" evidence="43">
<original>S</original>
<variation>P</variation>
<location>
<position position="1297"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070484" evidence="81">
<location>
<position position="1297"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs273900719." id="VAR_070485" evidence="81">
<original>S</original>
<variation>R</variation>
<location>
<position position="1301"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357407." id="VAR_070486" evidence="81">
<original>E</original>
<variation>K</variation>
<location>
<position position="1346"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28897689." id="VAR_007785" evidence="35">
<original>R</original>
<variation>G</variation>
<location>
<position position="1347"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs28897690." id="VAR_070487" evidence="81">
<original>V</original>
<variation>I</variation>
<location>
<position position="1378"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357306." id="VAR_070488" evidence="81">
<original>M</original>
<variation>V</variation>
<location>
<position position="1400"/>
</location>
</feature>
<feature type="sequence variant" description="Polymorphism; dbSNP:rs1800707." id="VAR_008761">
<original>K</original>
<variation>N</variation>
<location>
<position position="1406"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357492." id="VAR_070489" evidence="81">
<original>L</original>
<variation>P</variation>
<location>
<position position="1407"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and ovarian cancer; unknown pathological significance; decreased interaction with PALB2; dbSNP:rs273900729." id="VAR_020699" evidence="46 71 81">
<original>M</original>
<variation>T</variation>
<location>
<position position="1411"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_007786">
<original>S</original>
<variation>P</variation>
<location>
<position position="1431"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs41293455." id="VAR_007787" evidence="81 90 99">
<original>R</original>
<variation>G</variation>
<location>
<position position="1443"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs4986849." id="VAR_020112">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1443"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357486." id="VAR_070490" evidence="81">
<original>S</original>
<variation>G</variation>
<location>
<position position="1448"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs397507232." id="VAR_070491" evidence="81">
<original>S</original>
<variation>C</variation>
<location>
<position position="1486"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357389." id="VAR_063900" evidence="63">
<original>R</original>
<variation>M</variation>
<location>
<position position="1495"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1800744." id="VAR_007788" evidence="35 99 103">
<original>S</original>
<variation>I</variation>
<location>
<position position="1512"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs55815649." id="VAR_070492" evidence="81">
<original>V</original>
<variation>M</variation>
<location>
<position position="1534"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast cancer; unknown pathological significance; dbSNP:rs56158747." id="VAR_007789">
<original>T</original>
<variation>I</variation>
<location>
<position position="1561"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070493" evidence="81">
<original>R</original>
<variation>P</variation>
<location>
<position position="1589"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast cancer; unknown pathological significance; dbSNP:rs80356943." id="VAR_007790">
<original>K</original>
<variation>E</variation>
<location>
<position position="1606"/>
</location>
</feature>
<feature type="sequence variant" description="Common polymorphism; dbSNP:rs1799966." id="VAR_007791" evidence="21 39 54 91 98 106">
<original>S</original>
<variation>G</variation>
<location>
<position position="1613"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs8176219." id="VAR_019946" evidence="106">
<original>T</original>
<variation>A</variation>
<location>
<position position="1620"/>
</location>
</feature>
<feature type="sequence variant" description="Could be associated with cancer susceptibility; major splicing aberration identified with this mutant; dbSNP:rs80356862." id="VAR_063901" evidence="63 76">
<original>A</original>
<variation>G</variation>
<location>
<position position="1623"/>
</location>
</feature>
<feature type="sequence variant" description="In some patients with sporadic breast cancer; unknown pathological significance; dbSNP:rs4986854." id="VAR_007793" evidence="52 81">
<original>M</original>
<variation>T</variation>
<location>
<position position="1628"/>
</location>
</feature>
<feature type="sequence variant" description="Found in breast and ovarian cancer patients; unknown pathological significance; dbSNP:rs80357465." id="VAR_007792">
<original>M</original>
<variation>V</variation>
<location>
<position position="1628"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs80357048." id="VAR_007794" evidence="92 99">
<original>P</original>
<variation>L</variation>
<location>
<position position="1637"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance; dbSNP:rs1800726." id="VAR_008762">
<original>A</original>
<variation>P</variation>
<location>
<position position="1641"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356938." id="VAR_070494" evidence="81">
<original>S</original>
<variation>F</variation>
<location>
<position position="1651"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs879254042." id="VAR_070495" evidence="81">
<original>S</original>
<variation>P</variation>
<location>
<position position="1651"/>
</location>
</feature>
<feature type="sequence variant" description="Rare polymorphism; dbSNP:rs1799967." id="VAR_007795" evidence="35 54 81 99">
<original>M</original>
<variation>I</variation>
<location>
<position position="1652"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357390." id="VAR_070496" evidence="81">
<original>S</original>
<variation>F</variation>
<location>
<position position="1655"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs28897695." id="VAR_052080">
<original>F</original>
<variation>C</variation>
<location>
<position position="1662"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs80357169." id="VAR_020700" evidence="49">
<original>V</original>
<variation>M</variation>
<location>
<position position="1665"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356890." id="VAR_063902" evidence="63">
<original>T</original>
<variation>A</variation>
<location>
<position position="1685"/>
</location>
</feature>
<feature type="sequence variant" description="Could be associated with cancer susceptibility; multifactorial likelihood analysis provides evidence for pathogenicity; dbSNP:rs80357043." id="VAR_063903" evidence="63 76">
<original>T</original>
<variation>I</variation>
<location>
<position position="1685"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs397509218." id="VAR_070497" evidence="81">
<original>H</original>
<variation>Q</variation>
<location>
<position position="1686"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs730882166." id="VAR_070498" evidence="81">
<original>H</original>
<variation>R</variation>
<location>
<position position="1686"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro." id="VAR_070499" evidence="81">
<location>
<position position="1688"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357061." id="VAR_063904" evidence="63">
<original>M</original>
<variation>R</variation>
<location>
<position position="1689"/>
</location>
</feature>
<feature type="sequence variant" description="In some patients with sporadic breast cancer; unknown pathological significance; dbSNP:rs397507239." id="VAR_020701" evidence="52">
<original>K</original>
<variation>Q</variation>
<location>
<position position="1690"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357034." id="VAR_070500" evidence="81">
<original>T</original>
<variation>I</variation>
<location>
<position position="1691"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance; dbSNP:rs80187739." id="VAR_008763">
<original>D</original>
<variation>N</variation>
<location>
<position position="1692"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; dbSNP:rs80356993." id="VAR_020702" evidence="46">
<original>C</original>
<variation>R</variation>
<location>
<position position="1697"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; strongly reduces affinity for a BRIP1 phosphopeptide; functionally impaired in vitro; dbSNP:rs41293459." id="VAR_070501" evidence="78 81">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1699"/>
</location>
</feature>
<feature type="sequence variant" description="In BC, ovarian cancer and FANCS; impairs protein stability; functionally impaired in vitro; dbSNP:rs55770810." id="VAR_075666" evidence="46 63 78 81 83">
<original>R</original>
<variation>W</variation>
<location>
<position position="1699"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356860." id="VAR_070502" evidence="81">
<original>G</original>
<variation>A</variation>
<location>
<position position="1706"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356860." id="VAR_063905" evidence="63 81">
<original>G</original>
<variation>E</variation>
<location>
<position position="1706"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; abolishes ACACA binding; dbSNP:rs28897696." id="VAR_007796" evidence="63 81 92">
<original>A</original>
<variation>E</variation>
<location>
<position position="1708"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_007797" evidence="52">
<original>V</original>
<variation>G</variation>
<location>
<position position="1713"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357094." id="VAR_063906" evidence="63">
<original>S</original>
<variation>R</variation>
<location>
<position position="1715"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357239." id="VAR_070503" evidence="81">
<original>W</original>
<variation>C</variation>
<location>
<position position="1718"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; no effect on in vitro phosphorylation by ATR; dbSNP:rs56195342." id="VAR_070504" evidence="26 81">
<original>T</original>
<variation>A</variation>
<location>
<position position="1720"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs397509238." id="VAR_070505" evidence="81">
<original>E</original>
<variation>K</variation>
<location>
<position position="1735"/>
</location>
</feature>
<feature type="sequence variant" description="In BC and FANCS; unknown pathological significance; Decreased localization to DNA damage sites and reduced interaction with UIMC1/RAP80; dbSNP:rs45553935." id="VAR_070506" evidence="80 81">
<original>V</original>
<variation>A</variation>
<location>
<position position="1736"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80356937." id="VAR_063907" evidence="63">
<original>G</original>
<variation>R</variation>
<location>
<position position="1738"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357227." id="VAR_070507" evidence="81">
<original>D</original>
<variation>G</variation>
<location>
<position position="1739"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357227." id="VAR_070508" evidence="81">
<original>D</original>
<variation>V</variation>
<location>
<position position="1739"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs786202389." id="VAR_070509" evidence="81">
<original>H</original>
<variation>Q</variation>
<location>
<position position="1746"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance; abolishes ACACA binding and strongly reduces BRIP1 binding; dbSNP:rs80357462." id="VAR_007798" evidence="22 28 51">
<original>P</original>
<variation>R</variation>
<location>
<position position="1749"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs397509246." id="VAR_070510" evidence="81">
<original>R</original>
<variation>T</variation>
<location>
<position position="1753"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357281." id="VAR_063908" evidence="63 81">
<original>L</original>
<variation>P</variation>
<location>
<position position="1764"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357463." id="VAR_063909" evidence="63">
<original>I</original>
<variation>S</variation>
<location>
<position position="1766"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070511" evidence="81">
<original>C</original>
<variation>S</variation>
<location>
<position position="1767"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs863224765." id="VAR_070512" evidence="81">
<original>G</original>
<variation>V</variation>
<location>
<position position="1770"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; strongly reduced transcription transactivation; abolishes interaction with BRIP1 and RBBP8; dbSNP:rs41293463." id="VAR_063212" evidence="65">
<original>M</original>
<variation>K</variation>
<location>
<position position="1775"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; alters protein stability and abolishes ACACA and BRIP1 binding; dbSNP:rs41293463." id="VAR_007799" evidence="28 38 51 89 92">
<original>M</original>
<variation>R</variation>
<location>
<position position="1775"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance; dbSNP:rs1800757." id="VAR_008764">
<original>P</original>
<variation>S</variation>
<location>
<position position="1776"/>
</location>
</feature>
<feature type="sequence variant" description="In BC, BROVCA1 and OC; unknown pathological significance; dbSNP:rs80357474." id="VAR_079607" evidence="87">
<original>L</original>
<variation>P</variation>
<location>
<position position="1780"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070513" evidence="81">
<original>W</original>
<variation>C</variation>
<location>
<position position="1782"/>
</location>
</feature>
<feature type="sequence variant" description="In BROVCA1; unknown pathological significance; dbSNP:rs398122697." id="VAR_020704" evidence="43">
<original>L</original>
<variation>P</variation>
<location>
<position position="1786"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; dbSNP:rs80357069." id="VAR_063910" evidence="63">
<original>G</original>
<variation>V</variation>
<location>
<position position="1788"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80357078." id="VAR_070514" evidence="81">
<original>A</original>
<variation>T</variation>
<location>
<position position="1789"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs397509275." id="VAR_070515" evidence="81">
<original>E</original>
<variation>D</variation>
<location>
<position position="1794"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80356920." id="VAR_070516" evidence="81">
<original>V</original>
<variation>D</variation>
<location>
<position position="1804"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro." id="VAR_070517" evidence="81">
<original>P</original>
<variation>R</variation>
<location>
<position position="1812"/>
</location>
</feature>
<feature type="sequence variant" description="In ovarian cancer; unknown pathological significance; dbSNP:rs1800751." id="VAR_008765">
<original>P</original>
<variation>S</variation>
<location>
<position position="1812"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally impaired in vitro; dbSNP:rs80356959." id="VAR_070518" evidence="81">
<original>W</original>
<variation>R</variation>
<location>
<position position="1837"/>
</location>
</feature>
<feature type="sequence variant" description="In BC; unknown pathological significance; functionally neutral in vitro; dbSNP:rs80357183." id="VAR_070519" evidence="81">
<original>H</original>
<variation>L</variation>
<location>
<position position="1862"/>
</location>
</feature>
<feature type="mutagenesis site" description="Disrupts the interaction with E2 enzymes, thereby abolishing the E3 ubiquitin-protein ligase activity." evidence="58 74">
<original>I</original>
<variation>A</variation>
<location>
<position position="26"/>
</location>
</feature>
<feature type="mutagenesis site" description="No ubiquitination of RBBP8. No restoration RBBP8-mediated focus formation or G2/M checkpoint control upon DNA damage." evidence="58 74">
<original>I</original>
<variation>E</variation>
<location>
<position position="26"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on interaction with BAP1." evidence="100">
<original>R</original>
<variation>G</variation>
<location>
<position position="71"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes phosphorylation by AURKA and interferes with cell cycle progression from G2 to mitosis." evidence="48">
<original>S</original>
<variation>N</variation>
<location>
<position position="308"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1143"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1239"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1280"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1298"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1330"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of IR-induced S-phase checkpoint. Reduces in vitro phosphorylation by ATR." evidence="26 34">
<original>S</original>
<variation>A</variation>
<location>
<position position="1387"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces in vitro phosphorylation by ATR." evidence="26">
<original>T</original>
<variation>A</variation>
<location>
<position position="1394"/>
</location>
</feature>
<feature type="mutagenesis site" description="Inhibition of the infrared-induced G2 arrest. Reduces phosphorylation by ATR." evidence="26 34">
<original>S</original>
<variation>A</variation>
<location>
<position position="1423"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1457"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1466"/>
</location>
</feature>
<feature type="mutagenesis site" description="No change in infrared S-phase delay; when associated with A-1387. No effect on in vitro phosphorylation by ATR." evidence="26 34">
<original>S</original>
<variation>A</variation>
<location>
<position position="1524"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with BRIP1." evidence="51">
<original>S</original>
<variation>A</variation>
<location>
<position position="1655"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on affinity for a BRIP1 phosphopeptide." evidence="78">
<original>G</original>
<variation>D</variation>
<location>
<position position="1656"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1." evidence="84">
<original>F</original>
<variation>S</variation>
<location>
<position position="1662"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1." evidence="84">
<original>M</original>
<variation>K</variation>
<location>
<position position="1663"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not abolish ABRAXAS1 binding, but impairs formation of a heterotetramer with ABRAXAS1." evidence="84">
<original>Y</original>
<variation>A</variation>
<location>
<position position="1666"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs formation of a heterotetramer with ABRAXAS1." evidence="84">
<original>R</original>
<variation>E</variation>
<location>
<position position="1670"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs formation of a heterotetramer with ABRAXAS1." evidence="84">
<original>K</original>
<variation>E</variation>
<location>
<position position="1671"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduces affinity for a BRIP1 phosphopeptide." evidence="78">
<original>T</original>
<variation>A</variation>
<location>
<position position="1700"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with BRIP1." evidence="51">
<original>K</original>
<variation>M</variation>
<location>
<position position="1702"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with BRIP1." evidence="51">
<original>G</original>
<variation>E</variation>
<location>
<position position="1738"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on in vitro phosphorylation by ATR." evidence="26">
<original>S</original>
<variation>A</variation>
<location>
<position position="1755"/>
</location>
</feature>
<feature type="mutagenesis site" description="Mildly reduces affinity for a BRIP1 phosphopeptide." evidence="78">
<original>R</original>
<variation>P</variation>
<location>
<position position="1835"/>
</location>
</feature>
<feature type="mutagenesis site" description="Slightly reduces affinity for a BRIP1 phosphopeptide." evidence="78">
<original>E</original>
<variation>K</variation>
<location>
<position position="1836"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 4; AAB61673." ref="4" evidence="110">
<original>I</original>
<variation>T</variation>
<location>
<position position="89"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 4; AAB61673." ref="4" evidence="110">
<location>
<position position="148"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; AAC00049." ref="3" evidence="110">
<original>A</original>
<variation>V</variation>
<location>
<position position="253"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8; AAI15038." ref="8" evidence="110">
<original>S</original>
<variation>P</variation>
<location>
<position position="713"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 4; AAB61673." ref="4" evidence="110">
<original>G</original>
<variation>R</variation>
<location>
<position position="1077"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; AAC00049." ref="3" evidence="110">
<original>S</original>
<variation>P</variation>
<location>
<position position="1426"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8; AAI15038." ref="8" evidence="110">
<original>E</original>
<variation>G</variation>
<location>
<position position="1527"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="3"/>
<end position="5"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="8"/>
<end position="21"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="25"/>
<end position="27"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="46"/>
<end position="53"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="54"/>
<end position="58"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="62"/>
<end position="64"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="70"/>
<end position="72"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="78"/>
<end position="80"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="81"/>
<end position="96"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1651"/>
<end position="1656"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1659"/>
<end position="1671"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1675"/>
<end position="1679"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1686"/>
<end position="1689"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1695"/>
<end position="1697"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1701"/>
<end position="1708"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1712"/>
<end position="1715"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1717"/>
<end position="1725"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1731"/>
<end position="1734"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="1740"/>
<end position="1742"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1743"/>
<end position="1745"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1748"/>
<end position="1754"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="1755"/>
<end position="1757"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="1760"/>
<end position="1763"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1765"/>
<end position="1768"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="1770"/>
<end position="1772"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1773"/>
<end position="1775"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1777"/>
<end position="1786"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1790"/>
<end position="1794"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1795"/>
<end position="1797"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1801"/>
<end position="1803"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1806"/>
<end position="1810"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1812"/>
<end position="1814"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1817"/>
<end position="1819"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1820"/>
<end position="1822"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1824"/>
<end position="1827"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="1828"/>
<end position="1830"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1832"/>
<end position="1834"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1835"/>
<end position="1844"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="1851"/>
<end position="1853"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1JM7"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1OQA"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1T29"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1T2V"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3PXE"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4IGK"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="17081983"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="19690332"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="22814378"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25218447"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25755297"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="28112733"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P48754"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00033"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00175"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10196379"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10323242"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10486320"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10500182"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10724175"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10783165"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11114888"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11239454"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11301010"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11573085"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11739404"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11751867"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11836499"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11877377"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12183412"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12215251"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12360400"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12419185"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12427738"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12442274"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12442275"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12887909"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12890688"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12938098"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14636569"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14722926"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14746861"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14976165"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14990569"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15026808"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15096610"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15133502"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15365993"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15456891"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16101277"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16326698"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16698035"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16818604"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16959974"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17525340"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17643121"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17643122"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17924331"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18056443"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18285836"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18452305"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18762988"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19261746"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19261748"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19261749"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19369211"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20159462"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20160719"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20351172"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20364141"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20513136"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21144835"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21473589"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21673012"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23269703"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23867111"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24316840"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25472942"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26778126"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26807646"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28319063"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28364669"/>
</source>
</evidence>
<evidence key="88" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29133208"/>
</source>
</evidence>
<evidence key="89" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7545954"/>
</source>
</evidence>
<evidence key="90" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7894491"/>
</source>
</evidence>
<evidence key="91" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7894493"/>
</source>
</evidence>
<evidence key="92" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7939630"/>
</source>
</evidence>
<evidence key="93" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8554067"/>
</source>
</evidence>
<evidence key="94" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8723683"/>
</source>
</evidence>
<evidence key="95" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8776600"/>
</source>
</evidence>
<evidence key="96" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8968716"/>
</source>
</evidence>
<evidence key="97" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8972225"/>
</source>
</evidence>
<evidence key="98" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9010228"/>
</source>
</evidence>
<evidence key="99" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9482581"/>
</source>
</evidence>
<evidence key="100" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9528852"/>
</source>
</evidence>
<evidence key="101" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9609997"/>
</source>
</evidence>
<evidence key="102" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9662397"/>
</source>
</evidence>
<evidence key="103" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9760198"/>
</source>
</evidence>
<evidence key="104" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9811458"/>
</source>
</evidence>
<evidence key="105" type="ECO:0000269">
<source ref="5"/>
</evidence>
<evidence key="106" type="ECO:0000269">
<source ref="6"/>
</evidence>
<evidence key="107" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="108" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="9010228"/>
</source>
</evidence>
<evidence key="109" type="ECO:0000303">
<source ref="4"/>
</evidence>
<evidence key="110" type="ECO:0000305"/>
<sequence length="1863" mass="207721" checksum="89C6D83FF56312AF" modified="1995-02-01" version="2">
MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQ
CPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKD
EVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYI
ELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQ
PSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVE
KAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPC
SENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVD
EYSGSSEKIDLLASDPHEALICKSERVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTEN
LIIGAFVTEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTE
QNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNMELELNI
HNSKAPKKNRLRRKSSTRHIHALELVVSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPV
RHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKE
FVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQ
ESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHS
RETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVT
FECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRG
NETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIP
STVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKL
NAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSS
HASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQ
GYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENL
LSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGS
SKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSE
DCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALE
DLRNPEQSTSEKAVLTSQKSSEYPISQNPEGLSADKFEVSADSSTSKNKEPGVERSSPSK
CPSLDDRWYMHSCSGSLQNRNYPSQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEG
TPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTT
DTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLI
TEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDV
VNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTL
GTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPH
SHY
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>